<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LAMOTRIGINE- lamotrigine tablet </strong><br>Apotex Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="None">LAMOTRIGINE</span> tablets safely and effectively. See full prescribing information for <span class="None">LAMOTRIGINE</span> tablets. <br><br>LAMOTRIGINE tablets, USP, for oral use <br>Initial U.S. Approval: 1994 </div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASHES</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning. </span></h1>
<p class="Highlighta"><span class="Bold">Cases of life-threatening serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and/or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been caused by lamotrigine. The rate of serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is greater in pediatric patients than in adults. Additional factors that may increase the risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> include:</span> </p>
<p class="Highlighta">• <span class="Bold">coadministration with valproate </span> </p>
<p class="Highlighta">• <span class="Bold">exceeding recommended initial dose of lamotrigine tablets </span> </p>
<p class="Highlighta">• <span class="Bold">exceeding recommended dose escalation for lamotrigine tablets. (<a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">5.1</a>)</span> </p>
<p class="Highlighta"><span class="Bold"><span class="Bold">Benign <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> are also caused by lamotrigine; however, it is not possible to predict which <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> will prove to be serious or life-threatening. Lamotrigine tablets should be discontinued at the first sign of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, unless the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is clearly not drug related. (</span><a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">5.1</a>) </span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> Dosage and Administration (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>, <a href="#_79b34305-d79a-e6b9-a53f-988b4fb3cb80">2.2</a>, <a href="#_e2903c00-2cc1-ec25-9386-59e8f672a0b5">2.4</a>) 12/2014 </p>
<p class="Highlighta">Warnings and Precautions, Laboratory Tests (<a href="#_2DD07307-5038-36E9-6925-FDAA81A7B83E">5.14</a>) 3/2015  </p>
</div>
</div>
<div><div></div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASHES</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning. </span></h1>
<p class="Highlighta"><span class="Bold">Cases of life-threatening serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and/or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been caused by lamotrigine. The rate of serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is greater in pediatric patients than in adults. Additional factors that may increase the risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> include:</span> </p>
<p class="Highlighta">• <span class="Bold">coadministration with valproate </span> </p>
<p class="Highlighta">• <span class="Bold">exceeding recommended initial dose of lamotrigine tablets </span> </p>
<p class="Highlighta">• <span class="Bold">exceeding recommended dose escalation for lamotrigine tablets. (<a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">5.1</a>)</span> </p>
<p class="Highlighta"><span class="Bold"><span class="Bold">Benign <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> are also caused by lamotrigine; however, it is not possible to predict which <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> will prove to be serious or life-threatening. Lamotrigine tablets should be discontinued at the first sign of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, unless the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is clearly not drug related. (</span><a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">5.1</a>) </span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Lamotrigine tablets, USP are indicated for:   </p>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span>—<span class="Bold">adjunctive therapy in patients aged 2 years <span class="Bold">and older</span>:</span> </p>
<p class="Highlighta">• Partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.  </p>
<p class="Highlighta">• primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>.  </p>
<p class="Highlighta">• generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> of Lennox-Gastaut syndrome. (<a href="#_8A893987-AABC-5889-B069-8604DC89248E">1.1</a>) </p>
<p class="Highlighta"><span class="Bold">Epilepsy—monotherapy in patients </span><span class="Bold">aged</span><span class="Bold"> 16 years <span class="Bold">and older</span>: </span>Conversion to monotherapy in patients with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. (<a href="#_8A893987-AABC-5889-B069-8604DC89248E">1.1</a>)  </p>
<p class="Highlighta"><span class="Bold">Bipolar disorder in patients <span class="Bold">aged </span> </span><span class="Bold">18 years <span class="Bold">and older</span>: </span>Maintenance treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (<a href="#_08E61753-F3A2-E472-C1EF-7376F23E9A60">1.2</a>)  </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">• Dosing is based on concomitant medications, indication, and patient age. (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>, <a href="#_79b34305-d79a-e6b9-a53f-988b4fb3cb80">2.2</a>, <a href="#_D204D889-DE03-9A38-6B22-12DF857B89AD">2.3</a>, <a href="#_e2903c00-2cc1-ec25-9386-59e8f672a0b5">2.4</a>) </p>
<p class="Highlighta">• To avoid an increased risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, the recommended initial dose and subsequent dose escalations should not be exceeded (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>).  </p>
<p class="Highlighta">• Do not restart lamotrigine tablets in patients who discontinued due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> unless the potential benefits clearly outweigh the risks. (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>, <a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">5.1</a>) </p>
<p class="Highlighta">• Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>, <a href="#_95924841-207B-D6A0-784D-FDC6FEF07711">5.8</a>)  </p>
<p class="Highlighta">• Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>, <a href="#_F5D88172-4476-75E5-A589-D130B33A634C">5.9</a>)  </p>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span> </p>
<p class="Highlighta">• Adjunctive therapy—See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12 years. (<a href="#_F25CC454-B3E4-48A2-558D-ABE14758A068">2.2</a>)  </p>
<p class="Highlighta">• Conversion to monotherapy—See Table 4. (<a href="#_D204D889-DE03-9A38-6B22-12DF857B89AD">2.3</a>)  </p>
<p class="Highlighta"><span class="Bold">Bipolar disorder:</span> See Tables 5 and 6. (<a href="#_B71AB6D7-3080-9A20-E551-C95D015DF67C">2.4</a>)  </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"><span class="Bold">Tablets: </span>25 mg, 100 mg, 150 mg, and 200 mg; scored. (<a href="#_F879CBD7-7A02-1A5E-1438-FDF8F7372F0F">3.1</a>, <a href="#HOW_SUPPLIED">16</a>)  </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the drug or its ingredients. (Boxed Warning,<a href="#CONTRAINDICATIONS"> 4</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">• Life-threatening serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>: Discontinue at the first sign of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, unless the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is clearly not drug related. (Boxed Warning, <a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">5.1</a>)  </p>
<p class="Highlighta">• Fatal or life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>: Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, also known as drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), may be fatal or life threatening. Early signs may include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>. These reactions may be associated with other organ involvement, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, or acute <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiorgan failure</span>. Lamotrigine  should be discontinued if alternate etiology for this reaction is not found. (<a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">5.2</a>) </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> (e.g., <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>): May occur, either with or without an associated <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span>. Monitor for signs of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, unexpected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#_FD4A7CAE-F5AA-57D5-B3DC-30D6C2386FB8">5.3</a>) </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> and ideation: Monitor for suicidal thoughts or behaviors. (<a href="#_041AE776-AB46-DF3B-06A8-1EA3EC330FCF">5.4</a>)  </p>
<p class="Highlighta">• Clinical worsening, emergence of new symptoms, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>/behaviors may be associated with treatment of bipolar disorder. Patients should be closely monitored, particularly early in treatment or during dosage changes. (<a href="#_2990E853-DB04-CEF8-A9EB-8A0AE0E19015">5.5</a>)  </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span>: Monitor for signs of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. (<a href="#_65D45091-7981-6A48-54DA-13ED0D680BB5">5.6</a>)  </p>
<p class="Highlighta">• Medication errors due to product name <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>: Strongly advise patients to visually inspect tablets to verify the received drug is correct. (<a href="#_4CC26A9A-CDB0-C88E-5FDE-5993FD0695A8">5.7</a>, <a href="#HOW_SUPPLIED">16</a>, <a href="#INFORMATION_FOR_PATIENTS">17</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">• <span class="Bold"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>: </span> Most common adverse reactions (incidence ≥10%) in adults were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Additional adverse reactions (incidence ≥10%) reported in children included <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. (6.1)  </p>
<p class="Highlighta">• <span class="Bold">Bipolar disorder:</span> Most common adverse reactions (incidence &gt;5%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">xerostomia</span>. (6.1)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or </span><span class="Bold"><a href="http://www.fda.gov/medwatch"> www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">• Valproate increases lamotrigine concentrations more than 2-fold. (<a href="#DRUG_INTERACTIONS">7</a>, <a href="#PHARMACOKINETICS">12.3</a>)  </p>
<p class="Highlighta">• Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin decrease lamotrigine concentrations by approximately 40%. (<a href="#DRUG_INTERACTIONS">7</a>, <a href="#PHARMACOKINETICS">12.3</a>)  </p>
<p class="Highlighta">• Estrogen-containing oral contraceptives decrease lamotrigine concentrations by approximately 50%. (<a href="#DRUG_INTERACTIONS">7</a>, <a href="#PHARMACOKINETICS">12.3</a>) </p>
<p class="Highlighta">• Protease inhibitors lopinavir/ritonavir and atazanavir/lopinavir decrease lamotrigine exposure by approximately 50% and 32%, respectively. (<a href="#DRUG_INTERACTIONS">7</a>, <a href="#PHARMACOKINETICS">12.3</a>) </p>
<p class="Highlighta">• Coadministration with organic cationic transporter 2 substrates with narrow therapeutic index is not recommended (<a href="#DRUG_INTERACTIONS">7</a>, <a href="#PHARMACOKINETICS">12.3</a>)  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">• Pregnancy: Based on animal data may cause fetal harm. (<a href="#PREGNANCY">8.1</a>)   </p>
<p class="Highlighta">• Efficacy of lamotrigine tablets, used as adjunctive treatment for partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, was not demonstrated in a small, randomized, double-blind, placebo-controlled trial in very young pediatric patients (1 to 24 months). (<a href="#PEDIATRIC_USE">8.4</a>)  </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Dosage adjustments required in patients with moderate and severe liver impairment. (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>, <a href="#_8026C201-30A0-9505-7E08-04E7CFCBA83D">8.6</a>) </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Reduced maintenance doses may be effective for patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">2.1</a>, <a href="#_C91873C0-ADD1-677A-C099-D730DE9A4549">8.7</a>)  </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASHES</span></span></a></h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"> 1.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </a></h2>
<h2><a href="#section-1.2" class="toc"> 1.2 Bipolar Disorder </a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="None">2.1  General Dosing Considerations</span><span class="Bold">   </span></a></h2>
<h2><a href="#section-2.2" class="toc"> 2.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>-Adjunctive Therapy<span class="Bold"></span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="None">2.3 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>-Conversion from Adjunctive Therapy to Monotherapy </span></a></h2>
<h2><a href="#section-2.4" class="toc"> 2.4 Bipolar Disorder </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h2><a href="#section-3.1" class="toc"> 3.1 Tablets </a></h2>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="None">5.1 Serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin Rashes</span>  </span><span class="Italics">[see Boxed Warning]</span><span class="None"></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="None">5.2 Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> and Organ Failure </span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="None">5.3 <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span> </span></a></h2>
<h2><a href="#section-5.4" class="toc"> 5.4 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation </a></h2>
<h2><a href="#section-5.5" class="toc"><span class="None">5.5 Use in Patients with Bipolar Disorder  </span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="None">5.6 <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> </span></a></h2>
<h2><a href="#section-5.7" class="toc"> 5.7 Potential Medication Errors<span class="Bold"></span></a></h2>
<h2><a href="#section-5.8" class="toc"> 5.8 Concomitant Use with Oral Contraceptives </a></h2>
<h2><a href="#section-5.9" class="toc"><span class="None">5.9 <span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal Seizures</span> </span></a></h2>
<h2><a href="#section-5.10" class="toc"> 5.10 <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status Epilepticus</span> </a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Sudden Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> (SUDEP)
                     </a></h2>
<h2><a href="#section-5.12" class="toc"><span class="None">5.12 Addition of Lamotrigine Tablets to a Multidrug Regimen that Includes Valproate </span></a></h2>
<h2><a href="#section-5.13" class="toc"> 5.13 Binding in the Eye and Other Melanin-Containing Tissues </a></h2>
<h2><a href="#section-5.14" class="toc"> 5.14 Laboratory Tests </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"> 6.1 Clinical Trial Experience  </a></h2>
<h2><a href="#section-6.2" class="toc"> 6.2 Other Adverse Reactions Observed in All Clinical Trials </a></h2>
<h2><a href="#section-6.3" class="toc"><span class="None">6.3 Postmarketing Experience </span></a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc"><span class="None">8.1 Pregnancy </span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="None">8.2 Labor and Delivery </span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="None">8.3 Nursing Mothers </span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="None">8.4 Pediatric Use </span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="None">8.5 Geriatric Use </span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="None">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></a></h2>
<h2><a href="#section-8.7" class="toc"><span class="None">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc"><span class="None">10.1 Human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> Experience </span></a></h2>
<h2><a href="#section-9.2" class="toc"> 10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> </a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc"><span class="None">12.1 Mechanism of Action </span></a></h2>
<h2><a href="#section-11.2" class="toc"> 12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-11.3" class="toc"><span class="None">12.3 Pharmacokinetics </span></a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc"> 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"><span class="None">14.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="None">14.2  Bipolar Disorder </span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Warning">
<a name="BOXED_WARNING"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASHES</span></span></h1>
<p class="First"><span class="Bold">Lamotrigine tablets can cause serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> requiring hospitalization and discontinuation of treatment. The incidence of these <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, which have included <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, is approximately 0.8% (8 per 1,000) in pediatric patients (<span class="Bold">aged </span>2 to 16 years) receiving lamotrigine tablets as adjunctive therapy for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and 0.3% (3 per 1,000) in adults on adjunctive therapy for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. In clinical trials of bipolar and other mood disorders, the rate of serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was 0.08% (0.8 per 1,000) in adult patients receiving lamotrigine tablets as initial monotherapy and 0.13% (1.3 per 1,000) in adult patients receiving lamotrigine tablets as adjunctive therapy. In a prospectively followed cohort of 1,983 pediatric patients (<span class="Bold">aged </span>2 to 16 years) with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> taking adjunctive lamotrigine tablets, there was 1 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. In worldwide postmarketing experience, rare cases of <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and/or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate. </span> </p>
<p><span class="Bold">Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> caused by lamotrigine tablets. There are suggestions, yet to be proven, that the risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may also be increased by (1) coadministration of lamotrigine tablets with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of lamotrigine tablets, or (3) exceeding the recommended dose escalation for lamotrigine tablets. However, cases have occurred in the absence of these factors. </span> </p>
<p><span class="Bold">Nearly all cases of life-threatening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> caused by lamotrigine tablets have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </span></p>
<p><span class="Bold">Although benign <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> are also caused by lamotrigine tablets, it is not possible to predict reliably which <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> will prove to be serious or life threatening. Accordingly, lamotrigine tablets should ordinarily be discontinued at the first sign of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, unless the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is clearly not drug-related. Discontinuation of treatment may not prevent a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> from becoming life threatening or permanently disabling or disfiguring </span><span class="Bold Italics">[</span><span class="Bold Italics">see <a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">Warnings and Precautions (5.1)</a></span><span class="Bold Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS_AND_USAGE"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34067-9">
<a name="_8A893987-AABC-5889-B069-8604DC89248E"></a><a name="section-1.1"></a><p></p>
<h2> 1.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </h2>
<p class="First"><span class="Bold Italics">Adjunctive Therapy</span></p>
<p>Lamotrigine tablets, USP are indicated as adjunctive therapy for the following <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types in patients aged 2 years and older: </p>
<p>• partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. </p>
<p>• primary generalized tonic-clonic (PGTC) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>• generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> of Lennox-Gastaut syndrome.<span class="Bold"> </span></p>
<p><span class="Bold Italics">Monotherapy</span></p>
<p>Lamotrigine tablets, USP are indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).  </p>
<p>Safety and effectiveness of lamotrigine have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_08E61753-F3A2-E472-C1EF-7376F23E9A60"></a><a name="section-1.2"></a><p></p>
<h2> 1.2 Bipolar Disorder </h2>
<p class="First">Lamotrigine tablets, USP are indicated for the maintenance treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> to delay the time to occurrence of mood episodes (<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, mixed episodes) in adults (aged 18 years and older) treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine in the acute treatment of mood episodes has not been established.  </p>
<p>The effectiveness of lamotrigine as maintenance treatment was established in 2 placebo-controlled trials in patients with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> as defined by DSM-IV <span class="Italics">[</span><span class="Italics">see <a href="#_2A78EA81-3F2C-BD5F-283E-344F18D700A5">Clinical Studies (14.2)</a></span><span class="Italics">]</span>. The physician who elects to prescribe lamotrigine for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34068-7">
<a name="_CB4FB20A-1970-7107-87BD-469701BF64CA"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="None">2.1  General Dosing Considerations</span><span class="Bold">   </span>
</h2>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></p>
<p>There are suggestions, yet to be proven, that the risk of severe, potentially life threatening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be increased by (1) coadministration of lamotrigine with valproate, (2) exceeding the recommended initial dose of lamotrigine, or (3) exceeding the recommended dose escalation for lamotrigine. However, cases have occurred in the absence of these factors <span class="Italics">[</span><span class="Italics">see <a href="#BOXED_WARNING">Boxed Warning</a></span><span class="Italics">]</span>. Therefore, it is important that the dosing recommendations be followed closely.  </p>
<p>The risk of nonserious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be  increased when the recommended initial dose and/or the rate of dose escalation for lamotrigine tablets is exceeded and in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> to other AEDs. </p>
<p>It is recommended that lamotrigine tablets not be restarted in patients who discontinued due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with prior treatment with lamotrigine unless the potential benefits clearly outweigh the risks. If the decision is made to restart a patient who has discontinued lamotrigine, the need to restart with the initial dosing recommendations should be assessed. The greater the interval of time since the previous dose, the greater consideration should be given to restarting with the initial dosing recommendations. If a patient has discontinued lamotrigine for a period of more than 5 half-lives, it is recommended that initial dosing recommendations and guidelines be followed. The half-life of lamotrigine is affected by other concomitant medications <span class="Italics">[</span><span class="Italics">see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span><span class="Italics">.</span> </p>
<p><span class="Bold Italics">Lamotrigine Tablets Added to Drugs Known to Induce or Inhibit Glucuronidation</span></p>
<p>Because lamotrigine is metabolized predominantly by glucuronic acid conjugation, drugs that are known to induce or inhibit glucuronidation may affect the apparent clearance of lamotrigine. Drugs that induce glucuronidation include carbamazepine, phenytoin, phenobarbital, primidone, rifampin, estrogen-containing oral contraceptives, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Valproate inhibits glucuronidation. For dosing considerations for lamotrigine in patients on estrogen-containing contraceptives and atazanavir/ritonavir, see below and Table 13. For dosing considerations for lamotrigine in patients on other drugs known to induce or inhibit glucuronidation, see Table 1, Table 2, Table 5, Table 6, and Table 13. </p>
<p><span class="Bold Italics">Target Plasma Levels for Patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> or Bipolar Disorder</span></p>
<p>A therapeutic plasma concentration range has not been established for lamotrigine. Dosing of lamotrigine tablets should be based on therapeutic response <span class="Italics">[</span><span class="Italics">see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. </p>
<p><span class="Bold Italics">Women Taking Estrogen-Containing Oral Contraceptives </span></p>
<p><span class="Italics">Starting Lamotrigine Tablets in Women Taking Estrogen-Containing Oral Contraceptives</span></p>
<p>Although estrogen-containing oral contraceptives have been shown to increase the clearance of lamotrigine <span class="Italics">[</span><span class="Italics">see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>, no adjustments to the recommended dose-escalation guidelines for lamotrigine tablets should be necessary solely based on the use of estrogen-containing oral contraceptives. Therefore, dose escalation should follow the recommended guidelines for initiating adjunctive therapy with lamotrigine tablets based on the concomitant AED or other concomitant medications (see Table 1 or Table 5). See below for adjustments to maintenance doses of lamotrigine tablets in women taking estrogen-containing oral contraceptives. </p>
<p><span class="Bold Italics">Adjustments to the Maintenance Dose of Lamotrigine Tablets in Women Taking Estrogen-Containing Oral Contraceptives</span></p>
<p><span class="Italics">(1) Taking Estrogen-Containing Oral Contraceptives</span><span class="Bold Italics"><br></span>In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation <span class="Italics">[see </span><span class="Italics"><a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>, the maintenance dose of lamotrigine tablets will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level. </p>
<p><span class="Italics">(2) Starting Estrogen-Containing Oral Contraceptives</span><span class="Bold Italics"><br></span> In women taking a stable dose of lamotrigine tablets and not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>, the maintenance dose will in most cases need to be increased by as much as 2-fold to maintain a consistent lamotrigine plasma level. The dose increases should begin at the same time that the oral contraceptive is introduced and continue, based on clinical response, no more rapidly than 50 to 100 mg/day every week. Dose increases should not exceed the recommended rate (see Table 1 or Table 5) unless lamotrigine plasma levels or clinical response support larger increases. Gradual transient increases in lamotrigine plasma levels may occur during the week of inactive hormonal preparation (pill-free week), and these increases will be greater if dose increases are made in the days before or during the week of inactive hormonal preparation. Increased lamotrigine plasma levels could result in additional adverse reactions, such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>. If adverse reactions attributable to lamotrigine tablets consistently occur during the pill-free week, dose adjustments to the overall maintenance dose may be necessary. Dose adjustments limited to the pill-free week are not recommended. For women taking lamotrigine tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>, no adjustment to the dose of lamotrigine tablets should be necessary. </p>
<p><span class="Italics">(3) Stopping Estrogen-Containing Oral Contraceptives </span><br> In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>, the maintenance dose of lamotrigine tablets will in most cases need to be decreased by as much as 50% in order to maintain a consistent lamotrigine plasma level. The decrease in dose of lamotrigine tablets should not exceed 25% of the total daily dose per week over a 2-week period, unless clinical response or lamotrigine plasma levels indicate otherwise <span class="Italics">[see </span><span class="Italics"><a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. In women taking lamotrigine tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>, no adjustment to the dose of lamotrigine tablets should be necessary.</p>
<p><span class="Bold Italics">Women and Other Hormonal Contraceptive Preparations or Hormone Replacement Therapy</span></p>
<p>The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the dosage of lamotrigine tablets in the presence of progestogens alone will likely not be needed. </p>
<p><span class="Bold Italics">Patients <span class="Bold">Taking Atazanavir/Ritonavir</span></span></p>
<p>While atazanavir/ritonavir does reduce the lamotrigine plasma concentration, no adjustments to the recommended dose-escalation guidelines for lamotrigine should be necessary solely based on the use of atazanavir/ritonavir. Dose escalation should follow the recommended guidelines for initiating adjunctive therapy with lamotrigine based on concomitant AED or other concomitant medications (see Tables 1, 2, and 5). In patients already taking maintenance doses of lamotrigine and not taking glucuronidation inducers, the dose of lamotrigine may need to be increased if atazanavir/ritonavir is added, or decreased if atazanavir/ritonavir is discontinued <span class="Italics">[see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>].</span></p>
<p><span class="Bold Italics">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Experience in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is limited. Based on a clinical pharmacology study in 24 subjects with mild, moderate, and severe liver impairment <span class="Italics">[see   <a href="#_8026C201-30A0-9505-7E08-04E7CFCBA83D">Use in Specific Populations (8.6)</a>, <a href="#PHARMACOKINETICS"> Clinical Pharmacology (12.3)</a>]</span>, the following general recommendations can be made. No dosage adjustment is needed in patients with mild liver impairment. Initial, escalation, and maintenance doses should generally be reduced by approximately 25% in patients with moderate and severe liver impairment without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> and 50% in patients with severe liver impairment with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>. Escalation and maintenance doses may be adjusted according to clinical response. </p>
<p><span class="Bold Italics">Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Initial doses of lamotrigine tablets should be based on patients' concomitant medications (see Tables 1 to 3 or Table 5); reduced maintenance doses may be effective for patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[</span><span class="Italics">see <span class="Italics"><a href="#_8026C201-30A0-9505-7E08-04E7CFCBA83D">Use in Specific Populations (8.7)</a></span>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)]</a></span>. Few patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have been evaluated during chronic treatment with lamotrigine tablets. Because there is inadequate experience in this population, lamotrigine tablets should be used with caution in these patients. </p>
<p><span class="Bold Italics">Discontinuation Strategy </span></p>
<p><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>: For patients receiving lamotrigine tablets in combination with other AEDs, a re-evaluation of all AEDs in the regimen should be considered if a change in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control or an appearance or worsening of adverse reactions is observed.  </p>
<p>If a decision is made to discontinue therapy with lamotrigine tablets, a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) is recommended unless safety concerns require a more rapid withdrawal <span class="Italics">[</span><span class="Italics">see <a href="#_F5D88172-4476-75E5-A589-D130B33A634C">Warnings and Precautions (5.9)</a></span><span class="Italics">].</span>  </p>
<p>Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation should prolong the half-life of lamotrigine; discontinuing valproate should shorten the half-life of lamotrigine.</p>
<p><span class="Bold Italics">Bipolar Disorder</span></p>
<p>In the controlled clinical trials, there was no increase in the incidence, type, or severity of adverse reactions following abrupt termination of lamotrigine tablets. In clinical trials in patients with bipolar disorder, 2 patients experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> shortly after abrupt withdrawal of lamotrigine tablets. </p>
<p>However, there were confounding factors that may have contributed to the occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in these patients with bipolar disorder. Discontinuation of lamotrigine tablets should involve a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) unless safety concerns require a more rapid withdrawal <span class="Italics">[</span><span class="Italics">see </span><span class="Italics"><a href="#_F5D88172-4476-75E5-A589-D130B33A634C">Warnings and Precautions (5.9)</a></span><span class="Italics">]</span>. <span class="Bold"> </span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_79b34305-d79a-e6b9-a53f-988b4fb3cb80"></a><a name="section-2.2"></a><p></p>
<h2> 2.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>-Adjunctive Therapy<span class="Bold"></span>
</h2>
<p class="First">This section provides specific dosing recommendations for patients older than 12 years and patients aged 2 to 12 years. Within each of these age-groups, specific dosing recommendations are provided depending upon concomitant AEDs or other concomitant medications (see Table 1 for patients older than 12 years and Table 2 for patients aged 2 to 12 years). A weight-based dosing guide for patients aged 2 to 12 years on concomitant valproate is provided in Table 3.  </p>
<p><span class="Bold Italics">Patients </span><span class="Bold Italics">Older than</span><span class="Bold Italics"> 12 Years</span></p>
<p>Recommended dosing guidelines are summarized in Table 1. </p>
<table frame="border" rules="all" width="90%">
<caption><span>Table 1. Escalation Regimen for Lamotrigine Tablets in Patients Older than 12 Years With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></caption>
<col align="left" valign="top" width="15%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<td align="left" colspan="1" rowspan="1"></td>
<td align="center" rowspan="1" valign="bottom">In Patients TAKING Valproate<span class="Sup">a</span>
</td>
<td align="center" rowspan="1" valign="bottom">In Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone<span class="Sup">b</span>, or Valproate<span class="Sup">a</span>
</td>
<td align="center" rowspan="1" valign="bottom">In Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone<span class="Sup">b</span> and NOT TAKING Valproate<span class="Sup">a</span>
</td>
</tr>
<tr>
<td align="left" colspan="1">Weeks 1 and 2</td>
<td align="center" rowspan="1">
<span class="Bold">25 mg every </span><span class="Bold Italics">other</span><span class="Bold"> day</span>
</td>
<td align="center" rowspan="1"><span class="Bold">25 mg every day</span></td>
<td align="center" rowspan="1"><span class="Bold">50 mg/day</span></td>
</tr>
<tr>
<td align="left" colspan="1">Weeks 3 and 4</td>
<td align="center" rowspan="1"><span class="Bold">25 mg every day</span></td>
<td align="center" rowspan="1"><span class="Bold">50 mg/day</span></td>
<td align="center" rowspan="1">
<span class="Bold">100 mg/day</span><br>(in 2 divided doses)</td>
</tr>
<tr>
<td align="left" colspan="1">Week 5 onward to maintenance</td>
<td align="center" rowspan="1">Increase by 25 to 50 mg/day every 1 to 2 weeks</td>
<td align="center" rowspan="1">Increase by 50 mg/day every 1 to 2 weeks</td>
<td align="center" rowspan="1">Increase by 100 mg/day every 1 to 2 weeks</td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Usual maintenance dose</td>
<td align="center" rowspan="1">
<span class="Bold">100 to 200 mg/day with valproate alone 100 to 400 mg/day with valproate and other drugs that induce glucuronidcation</span><br>(in 1 or 2 divided doses)</td>
<td align="center" rowspan="1">
<span class="Bold">225 to 375 mg/day</span><br>(in 2 divided doses)</td>
<td align="center" rowspan="1">
<span class="Bold">300 to 500 mg/day</span><br>(in 2 divided doses)</td>
</tr>
</tbody>
</table>
<span class="Bold"></span><p><span class="Sup">a</span>- Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS"> Drug Interactions (7)</a>,  <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. </p>
<p><span class="Sup">b</span>- Drugs that induce lamotrigine glucuronidation and increase clearance, other than the specified antiepileptic drugs, include estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations <span class="Italics">[</span><span class="Italics">see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1</a>)</span><span class="Italics">]</span>. Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance <span class="Italics">[</span><span class="Italics">see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>, <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, and <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">].</span></p>
<p><span class="Bold Italics">Patients <span class="Bold Italics">Aged</span> 2 to 12 Years</span></p>
<p>Recommended dosing guidelines are summarized in Table 2.  </p>
<p>Smaller starting doses and slower dose escalations than those used in clinical trials are recommended because of the suggestion that the risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be decreased by smaller starting doses and slower dose escalations. Therefore, maintenance doses will take longer to reach in clinical practice than in clinical trials. It may take several weeks to months to achieve an individualized maintenance dose. Maintenance doses in patients weighing less than 30 kg, regardless of age or concomitant AED, may need to be increased as much as 50%, based on clinical response.  </p>
<table frame="border" rules="all" width="90%">
<caption><span>Table 2. Escalation Regimen for Lamotrigine Tablets in Patients Aged 2 to 12 Years With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></caption>
<col align="left" valign="top" width="15%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="center" colspan="1" rowspan="1" valign="bottom">In Patients TAKING Valproate<span class="Sup">a</span>
</td>
<td align="center" rowspan="1" valign="bottom">In Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone<span class="Sup">b</span>, and or Valproate<span class="Sup">a</span>
</td>
<td align="center" rowspan="1" valign="bottom">In Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone<span class="Sup">b</span> and NOT TAKING Valproate<span class="Sup">a</span>
</td>
</tr>
<tr>
<td align="left" colspan="1">Weeks 1 and 2</td>
<td align="center" colspan="1">
<span class="Bold">0.15 mg/kg/day</span> in 1 or 2 divided doses, rounded down to the nearest whole tablet (see Table 3 for weight-based dosing guide)</td>
<td align="center" colspan="1">
<span class="Bold">0.3 mg/kg/day </span>in 1 or 2 divided doses, rounded down to the nearest whole tablet</td>
<td align="center" colspan="1">
<span class="Bold">0.6 mg/kg/day </span>in 2 divided doses, rounded down to the nearest whole tablet</td>
</tr>
<tr>
<td align="left" colspan="1">Weeks 3 and 4</td>
<td align="center" colspan="1">
<span class="Bold">0.3 mg/kg/day </span>in 1 or 2 divided doses, rounded down to the nearest whole tablet (see Table 3 for weight-based dosing guide)</td>
<td align="center" colspan="1">
<span class="Bold">0.6 mg/kg/day </span>in 2 divided doses, rounded down to the nearest whole tablet</td>
<td align="center" colspan="1">
<span class="Bold">1.2 mg/kg/day </span>in 2 divided doses, rounded down to the nearest whole tablet</td>
</tr>
<tr>
<td align="left" colspan="1">Week 5 onward to maintenance </td>
<td align="center" colspan="1">The dose should be increased every 1 to 2 weeks as follows: calculate 0.3 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose</td>
<td align="center" colspan="1">The dose should be increased every 1 to 2 weeks as follows: calculate 0.6 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose</td>
<td align="center" colspan="1">The dose should be increased every 1 to 2 weeks as follows: calculate 1.2 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose</td>
</tr>
<tr>
<td align="left" colspan="1">Usual Maintenance Dose</td>
<td align="center" colspan="1">
<span class="Bold">1 to 5 mg/kg/day </span>(maximum 200 mg/day in 1 or 2 divided doses). <span class="Bold">1 to 3 mg/kg/day </span>with valproate alone</td>
<td align="center" colspan="1">
<span class="Bold">4.5 to 7.5 mg/kg/day </span>(maximum 300 mg/day in 2 divided doses)</td>
<td align="center" colspan="1">
<span class="Bold">5 to 15 mg/kg/day </span>(maximum 400 mg/day in 2 divided doses)</td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Maintenance dose in patients less than 30 kg</td>
<td align="center" colspan="1">May need to be increased by as much as 50%, based on clinical response</td>
<td align="center" colspan="1">May need to be increased by as much as 50%, based on clinical response</td>
<td align="center" colspan="1">May need to be increased by as much as 50%, based on clinical response</td>
</tr>
</tbody>
</table>
<span class="Bold"></span><p><span class="Bold">Note: Only whole tablets should be used for dosing.</span></p>
<p><span class="Bold"></span><span class="Sup">a</span>- Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS"> Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">].</span></p>
<p><span class="Sup">b</span>- Drugs that induce lamotrigine glucuronidation and increase clearance, other than the specified antiepileptic drugs, include estrogen-containing oral contraceptives<span class="Italics">,</span> rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in <span class="Italics">General Dosing Considerations [see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>].</span> Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance <span class="Italics">[see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>, <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, and <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>].</span></p>
<table frame="border" rules="all" width="90%">
<caption><span>Table 3. The Initial Weight-Based Dosing Guide for Patients Aged 2 to 12 Years Taking Valproate (Weeks 1 to 4) With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></caption>
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<tbody class="Headless">
<tr class="First">
<td align="center" colspan="2" valign="bottom"> If the patient’s weight is </td>
<td align="center" colspan="2" valign="bottom"> Give this daily dose, using the most appropriate combination of<br> Lamotrigine 2-mg and 5-mg tablets </td>
</tr>
<tr align="center">
<td align="center" colspan="1">Greater than</td>
<td align="center" rowspan="1">And less than</td>
<td align="center" colspan="1">Weeks 1 and 2</td>
<td align="center" rowspan="1">Weeks 3 and 4</td>
</tr>
<tr align="center">
<td align="center" colspan="1">6.7 kg</td>
<td align="center" colspan="1">14 kg</td>
<td align="center" colspan="1">2 mg every <span class="Italics">other</span> day</td>
<td align="center" colspan="1">2 mg every day</td>
</tr>
<tr align="center">
<td align="center" colspan="1">14.1 kg</td>
<td align="center" colspan="1">27 kg</td>
<td align="center" colspan="1">2 mg every day</td>
<td align="center" colspan="1">4 mg every day</td>
</tr>
<tr align="center">
<td align="center" colspan="1">27.1 kg</td>
<td align="center" colspan="1">34 kg</td>
<td align="center" colspan="1">4 mg every day</td>
<td align="center" colspan="1">8 mg every day</td>
</tr>
<tr class="Last" align="center">
<td align="center" colspan="1">34.1 kg</td>
<td align="center" colspan="1">40 kg</td>
<td align="center" colspan="1">5 mg every day</td>
<td align="center" colspan="1">10 mg every day</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics">Usual Adjunctive Maintenance Dose for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></p>
<p>The usual maintenance doses identified in Tables 1 and 2 are derived from dosing regimens employed in the placebo-controlled adjunctive trials in which the efficacy of lamotrigine tablets was established. In patients receiving multidrug regimens employing carbamazepine, phenytoin, phenobarbital, or primidone <span class="Bold">without valproate</span>, maintenance doses of adjunctive lamotrigine tablets as high as 700 mg/day have been used. In patients receiving <span class="Bold">valproate alone</span>, maintenance doses of adjunctive lamotrigine tablets as high as 200 mg/day have been used. The advantage of using doses above those recommended in Tables 1 to 4 has not been established in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_D204D889-DE03-9A38-6B22-12DF857B89AD"></a><a name="section-2.3"></a><p></p>
<h2><span class="None">2.3 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>-Conversion from Adjunctive Therapy to Monotherapy </span></h2>
<p class="First">The goal of the transition regimen is to attempt to maintain <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control while mitigating the risk of serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with the rapid titration of lamotrigine tablets.  </p>
<p>The recommended maintenance dose of lamotrigine tablets as monotherapy is 500 mg/day given in 2 divided doses. </p>
<p>To avoid an increased risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, the recommended initial dose and subsequent dose escalations for lamotrigine tablets should not be exceeded <span class="Italics">[see Boxed Warning].</span>     </p>
<p><span class="Bold Italics">Conversion from Adjunctive Therapy with Carbamazepine, Phenytoin, Phenobarbital, or Primidone to Monotherapy With Lamotrigine Tablets</span></p>
<p>After achieving a dose of 500 mg/day of lamotrigine tablets using the guidelines in Table 1, the concomitant enzyme-inducing AED should be withdrawn by 20% decrements each week over a 4-week period. The regimen for the withdrawal of the concomitant AED is based on experience gained in the controlled monotherapy clinical trial. </p>
<p><span class="Bold Italics">Conversion from Adjunctive Therapy with Valproate to Monotherapy With Lamotrigine Tablets</span></p>
<p>The conversion regimen involves the 4 steps outlined in Table 4. </p>
<p><span class="Bold">Table 4. Conversion from Adjunctive </span><span class="Bold">Therapy with Valproate to Monotherapy With Lamotrigine </span><span class="Bold">Tablets <span class="Bold">in Patients </span>Aged <span class="Bold">16 Years and older with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></span></p>
<table border="" frame="border" rules="all" width="90%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<tbody class="Headless" align="left">
<tr class="First" align="center">
<td align="center"></td>
<td align="left" rowspan="1"><span class="Bold">Lamotrigine Tablets</span></td>
<td align="left" rowspan="1"><span class="Bold">Valproate</span></td>
</tr>
<tr align="center">
<td align="center" colspan="1">Step 1 </td>
<td align="left" colspan="1">Achieve a dose of 200 mg/day according to guidelines in Table 1</td>
<td align="left" colspan="1">Maintain established stable dose.</td>
</tr>
<tr align="center">
<td align="center" colspan="1">Step 2 </td>
<td align="left" colspan="1">Maintain at 200 mg/day.</td>
<td align="left" colspan="1">Decrease dose by decrements no greater than 500 mg/day/week to 500 mg/day and then maintain for 1 week.</td>
</tr>
<tr align="center">
<td align="center" colspan="1">Step 3 </td>
<td align="left" colspan="1">Increase to 300 mg/day and maintain for 1 week.</td>
<td align="left" colspan="1">Simultaneously decrease to 250 mg/day and maintain for 1 week.</td>
</tr>
<tr class="Last" align="center">
<td align="center" colspan="1">Step 4 </td>
<td align="left" colspan="1">Increase by 100 mg/day every week to achieve maintenance dose of 500 mg/day.</td>
<td align="left" colspan="1">Discontinue.</td>
</tr>
</tbody>
</table>
<span class="Bold"></span><p><span class="Bold Italics">Conversion from Adjunctive Therapy with <span class="Bold Italics">Antiepileptic Drugs</span> Other Than Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate to Monotherapy with Lamotrigine Tablets </span></p>
<p>No specific dosing <span class="Bold">guidelines</span> can be provided for conversion to monotherapy with lamotrigine tablets with AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_e2903c00-2cc1-ec25-9386-59e8f672a0b5"></a><a name="section-2.4"></a><p></p>
<h2> 2.4 Bipolar Disorder </h2>
<p class="First">The goal of maintenance treatment with lamotrigine tablets is to delay the time to occurrence of mood episodes (<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, mixed episodes) in patients treated for acute mood episodes with standard therapy. The target dose of lamotrigine tablets is 200 mg/day (100 mg/day in patients taking valproate, which decreases the apparent clearance of lamotrigine, and 400 mg/day in patients not taking valproate and taking either carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitor lopinavir/ritonavir that increase the apparent clearance of lamotrigine). In the clinical trials, doses up to 400 mg/day as monotherapy were evaluated; however, no additional benefit was seen at 400 mg/day compared with 200 mg/day <span class="Italics">[</span><span class="Italics">see <a href="#_2A78EA81-3F2C-BD5F-283E-344F18D700A5"> Clinical Studies (14.2)</a></span><span class="Italics">]</span><span class="Italics">.</span> Accordingly, doses above 200 mg/day are not recommended. Treatment with lamotrigine tablets is introduced, based on concurrent medications, according to the regimen outlined in Table 5. If other psychotropic medications are withdrawn following stabilization, the dose of lamotrigine tablets should be adjusted. For patients discontinuing valproate, the dose of lamotrigine tablets should be doubled over a 2-week period in equal weekly increments (see Table 6). For patients discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation, the dose of lamotrigine tablets should remain constant for the first week and then should be decreased by half over a 2-week period in equal weekly decrements (see Table 6). The dose of lamotrigine tablets may then be further adjusted to the target dose (200 mg) as clinically indicated.</p>
<p>If other drugs are subsequently introduced, the dose of lamotrigine tablets may need to be adjusted. In particular, the introduction of valproate requires reduction in the dose of lamotrigine tablets <span class="Italics">[see <a href="#DRUG_INTERACTIONS"> Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">].</span> </p>
<p>To avoid an increased risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, the recommended initial dose and subsequent dose escalations of lamotrigine tablets should not be exceeded <span class="Italics">[see <a href="#BOXED_WARNING">Boxed Warning</a>]</span><span class="Italics">.</span> </p>
<table frame="border" rules="all" width="90%">
<caption><span>Table 5. Escalation Regimen for Lamotrigine Tablets in Patients With Bipolar Disorder</span></caption>
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<tbody class="Headless" align="center">
<tr class="First" align="center">
<td align="left"></td>
<td align="center" valign="bottom">In Patients Taking Valproate<span class="Sup">a</span>
</td>
<td align="center" valign="bottom">In Patients NOT Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone<span class="Sup">b</span>, or Valproate<span class="Sup">a</span>
</td>
<td align="center">In Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone<span class="Sup">b</span>, and NOT Taking Valproate<span class="Sup">a</span>
</td>
</tr>
<tr>
<td align="left" colspan="1">Weeks 1 and 2</td>
<td align="center" rowspan="1" valign="middle">25 mg every <span class="Italics">other</span> day</td>
<td align="center" rowspan="1">25 mg daily</td>
<td align="center" rowspan="1">50 mg daily</td>
</tr>
<tr>
<td align="left" colspan="1">Weeks 3 and 4 </td>
<td align="center" rowspan="1">25 mg daily</td>
<td align="center" rowspan="1">50 mg daily</td>
<td align="center" rowspan="1">100 mg daily, in divided doses</td>
</tr>
<tr>
<td align="left" colspan="1">Week 5</td>
<td align="center" rowspan="1">50 mg daily</td>
<td align="center" rowspan="1">100 mg daily</td>
<td align="center" rowspan="1">200 mg daily, in divided doses</td>
</tr>
<tr>
<td align="left" colspan="1">Week 6 </td>
<td align="center" rowspan="1">100 mg daily</td>
<td align="center" rowspan="1">200 mg daily</td>
<td align="center" rowspan="1">300 mg daily, in divided doses</td>
</tr>
<tr class="Last" align="center">
<td align="left" colspan="1">Week 7 </td>
<td align="center" rowspan="1">100 mg daily</td>
<td align="center" rowspan="1">200 mg daily</td>
<td align="center" rowspan="1">up to 400 mg daily, in divided doses</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>- Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine <span class="Italics">[see <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, <a href="#PHARMACOKINETICS"> Clinical Pharmacology (12.3</a>)].</span></p>
<p><span class="Sup">b</span>- Drugs that induce lamotrigine glucuronidation and increase clearance<span class="Italics">,</span><span class="Italics"> other than the specified antiepileptic drugs,</span> include estrogen-containing oral contraceptives<span class="Italics">,</span><span class="Italics"> rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir.</span> Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations <span class="Italics">[</span><span class="Italics">see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a></span><span class="Italics">]</span>. Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance <span class="Italics">[</span><span class="Italics">see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>, <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, and <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. </p>
<p><span class="Bold">Table 6. Dosage Adjustments to Lamotrigine Tablets  for Patients With Bipolar Disorder Following Discontinuation of Psychotropic Medications</span></p>
<table frame="border"><tbody class="Headless" align="center">
<tr class="First">
<td rowspan="2"> </td>
<td align="left" rowspan="2">Discontinuation of Psychotropic Drugs (excluding <span class="None">, Valproate<span class="Sup">a</span>,</span> Carbamazepine, Phenytoin, Phenobarbital, or Primidone<span class="Sup">b</span>)</td>
<td align="left">After Discontinuation of Valproate<span class="Sup">a</span>
</td>
<td align="left">After Discontinuation of Carbamazepine, Phenytoin, Phenobarbital, or Primidone<span class="Sup">b</span>
</td>
</tr>
<tr>
<td align="left">Current dose of Lamotrigine Tablets (mg/day)<br>100</td>
<td align="left">Current dose of Lamotrigine Tablets (mg/day) <br>400</td>
</tr>
<tr>
<td>Week 1 </td>
<td align="left">Maintain current dose of lamotrigine tablets </td>
<td>150</td>
<td>400</td>
</tr>
<tr>
<td>Week 2 </td>
<td align="left">Maintain current dose of lamotrigine tablets </td>
<td>200</td>
<td>300</td>
</tr>
<tr class="Last">
<td>Week 3 onward </td>
<td align="left">Maintain current dose of lamotrigine tablets </td>
<td>200</td>
<td>200</td>
</tr>
</tbody></table>
<p><span class="Sup">a</span>-Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS"> Drug Interactions (7)</a>, <span class="Italics"><a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span></span><span class="Italics">].</span></p>
<p><span class="Sup">b</span>- Drugs that induce lamotrigine glucuronidation and increase clearance, <span class="Italics">other than the specified antiepileptic drugs,</span> include estrogen-containing oral contraceptives, <span class="Italics">rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir</span>. Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations <span class="Italics"><a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">[see Dosage and Administration (2.1)</a>].</span> Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance <span class="Italics">[</span><span class="Italics">see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>, <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>, and <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. </p>
<p>The benefit of continuing treatment in patients who had been stabilized in an 8- to 16- week open-label phase with lamotrigine tablets was established in 2 randomized, placebo-controlled clinical maintenance trials <span class="Italics">[</span><span class="Italics">see <a href="#_2A78EA81-3F2C-BD5F-283E-344F18D700A5">Clinical Studies (14.2)</a></span><span class="Italics">].</span> However, the optimal duration of treatment with lamotrigine tablets has not been established. Thus, patients should be periodically reassessed to determine the need for maintenance treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DOSAGE_FORMS_AND_STRENGTHS"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43678-2">
<a name="_F879CBD7-7A02-1A5E-1438-FDF8F7372F0F"></a><a name="section-3.1"></a><p></p>
<h2> 3.1 Tablets </h2>
<p class="First">25 mg, white to off white, round flat faced bevelled-edge tablets, engraved “LAM? over score “25? on one side, “APO? on the other side. </p>
<p>100 mg, peach, round, flat faced bevelled-edge tablets, engraved “LAM? over score “100? on one side, “APO? on the other side. </p>
<p>150 mg, cream, round, flat faced bevelled-edge tablets, engraved “LAM? over score “150? on one side, “APO? on the other side. </p>
<p>200 mg blue, round, flat faced bevelled-edge tablets, engraved “LAM? over score “200? on one side, “APO? on the other side.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Lamotrigine is contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">acute urticaria</span>, extensive <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="442121" conceptname="Mucosal ulcer">mucosal ulceration</span>) to the drug or its ingredients <span class="Italics">[</span><span class="Italics">see <a href="#BOXED_WARNING">Boxed Warning</a>, <a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">Warnings and Precautions (5.1</a>, </span><span class="Italics"><a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0"></a><a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">5.2)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="WARNINGS_AND_PRECAUTIONS"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43685-7">
<a name="_1B65B547-84BD-90EF-0CB2-F30527EDA77A"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="None">5.1 Serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin Rashes</span>  </span><span class="Italics">[see Boxed Warning]</span><span class="None"></span>
</h2>
<p class="First"><span class="Bold Italics">Pediatric Population</span></p>
<p>The incidence of serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with hospitalization and discontinuation of lamotrigine in a prospectively followed cohort of pediatric patients (aged 2 to 16 years) with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> receiving adjunctive therapy was approximately 0.8% (16 of 1,983). When 14 of these cases were reviewed by 3 expert dermatologists, there was considerable disagreement as to their proper classification. To illustrate, one dermatologist considered none of the cases to be <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>; another assigned 7 of the 14 to this diagnosis. There was 1 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in this 1,983-patient cohort. Additionally, there have been rare cases of <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> with and without permanent sequelae and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in US and foreign postmarketing experience. </p>
<p>There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in pediatric patients. In pediatric patients who used valproate concomitantly, 1.2% (6 of 482) experienced a serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> compared with 0.6% (6 of 952) patients not taking valproate.    </p>
<p><span class="Bold Italics">Adult Population</span></p>
<p>Serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with hospitalization and discontinuation of lamotrigine occurred in 0.3% (11 of 3,348) of adult patients who received lamotrigine tablets in premarketing clinical trials of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. In the bipolar and other mood disorders clinical trials, the rate of serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was 0.08% (1 of 1,233) of adult patients who received lamotrigine tablets as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received lamotrigine tablets as adjunctive therapy. No fatalities occurred among these individuals. However, in worldwide postmarketing experience, rare cases of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported, but their numbers are too few to permit a precise estimate of the rate.  </p>
<p>Among the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> leading to hospitalization were <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and those associated with multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="Italics">[see <a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">Warnings </a></span><a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">and </a><span class="Italics"><a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">Precautions (5.2)</a>]</span>. </p>
<p>There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in adults. Specifically, of 584 patients administered lamotrigine tablets with valproate in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> clinical trials, 6 (1%) were hospitalized in association with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; in contrast, 4 (0.16%) of 2,398 clinical trial patients and volunteers administered lamotrigine tablets in the absence of valproate were hospitalized.  </p>
<p><span class="Bold Italics">Patients With History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> to Other Antiepileptic Drugs</span></p>
<p>The risk of nonserious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be increased when the recommended initial dose and/or the rate of dose escalation for lamotrigine tablets is exceeded and in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> to other AEDs. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_7D99A3CE-2D69-6428-4F47-35B3A62230D0"></a><a name="section-5.2"></a><p></p>
<h2><span class="None">5.2 Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> and Organ Failure </span></h2>
<p class="First">Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, also known as drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), have occurred with lamotrigine. Some have been fatal or life threatening. DRESS typically, although not exclusively, presents with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and/or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> in association with other organ system involvement, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, or <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, sometimes resembling an acute <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. </p>
<p>Fatalities associated with acute <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiorgan failure</span> and various degrees of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported in 2 of 3,796 adult patients and 4 of 2,435 pediatric patients who received lamotrigine in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> clinical trials. Rare fatalities from <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiorgan failure</span> have also been reported in postmarketing use. </p>
<p>Isolated <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or involvement of other organs has also been reported with lamotrigine. It is important to note that early manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>) may be present even though a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Lamotrigine tablets should be discontinued if an alternative etiology for the signs or symptoms cannot be established. </p>
<p><span class="Bold">Prior to initiation of treatment with lamotrigine tablets, the patient should be instructed that a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately. </span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_041AE776-AB46-DF3B-06A8-1EA3EC330FCF"></a><a name="section-5.3"></a><p></p>
<h2><span class="None">5.3 <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span> </span></h2>
<p class="First">There have been reports of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> that may or may not be associated with multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (also known as DRESS) <span class="Italics">[see Warnings and Precautions (<a href="#_041AE776-AB46-DF3B-06A8-1EA3EC330FCF">5.2)</a>]</span><span class="Italics">.</span> These have included <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_2990E853-DB04-CEF8-A9EB-8A0AE0E19015"></a><a name="section-5.4"></a><p></p>
<h2> 5.4 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation </h2>
<p class="First">AEDs, including lamotrigine tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.  </p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared with patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated. There were 4 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.  </p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.  </p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanism of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.  </p>
<p>Table 7 shows absolute and relative risk by indication for all evaluated AEDs. </p>
<p><span class="Bold">Table 7. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</span></p>
<table frame="border" rules="all" width="100%"><tbody class="Headless">
<tr class="First" align="center">
<td>Indication</td>
<td align="left" rowspan="1">Placebo Patients With Events Per 1,000 Patients</td>
<td align="left" rowspan="1">Drug Patients With Events Per 1,000 Patients</td>
<td align="left" rowspan="1">Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients</td>
<td align="left" rowspan="1">Risk Difference: Additional Drug Patients With Events Per 1,000 Patients</td>
</tr>
<tr>
<td colspan="1"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></td>
<td align="center" colspan="1">1.0</td>
<td align="center" colspan="1">3.4</td>
<td align="center" colspan="1">3.5</td>
<td align="center" colspan="1">2.4</td>
</tr>
<tr>
<td colspan="1">Psychiatric</td>
<td align="center" colspan="1">5.7</td>
<td align="center" colspan="1">8.5</td>
<td align="center" colspan="1">1.5</td>
<td align="center" colspan="1">2.9</td>
</tr>
<tr>
<td colspan="1">Other</td>
<td align="center" colspan="1">1.0</td>
<td align="center" colspan="1">1.8</td>
<td align="center" colspan="1">1.9</td>
<td align="center" colspan="1">0.9</td>
</tr>
<tr class="Last">
<td colspan="1">Total</td>
<td align="center" colspan="1">2.4</td>
<td align="center" colspan="1">4.3</td>
<td align="center" colspan="1">1.8</td>
<td align="center" colspan="1">1.9</td>
</tr>
</tbody></table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.  </p>
<p>Anyone considering prescribing lamotrigine tablets or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.  </p>
<p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, the emergence of suicidal thoughts or <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_65D45091-7981-6A48-54DA-13ED0D680BB5"></a><a name="section-5.5"></a><p></p>
<h2><span class="None">5.5 Use in Patients with Bipolar Disorder  </span></h2>
<p class="First"><span class="Bold Italics">Acute Treatment of Mood Episodes </span></p>
<p>Safety and effectiveness of lamotrigine tablets in the acute treatment of mood episodes have not been established.  </p>
<p><span class="Bold Italics">Children and Adolescents (<span class="Bold Italics">younger</span> than 18 years)</span></p>
<p>Safety and effectiveness of lamotrigine tablets in patients younger than 18 years with mood disorders have not been established <span class="Italics">[</span><span class="Italics">see <a href="#_2990E853-DB04-CEF8-A9EB-8A0AE0E19015">Warnings and Precautions (5.4)</a></span><span class="Italics">]</span>. </p>
<p><span class="Bold Italics">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk Associated With Bipolar Disorder</span></p>
<p>Patients with bipolar disorder may experience worsening of their <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behaviors (suicidality) whether or not they are taking medications for bipolar disorder. Patients should be closely monitored for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of treatment or at the time of dose changes.  </p>
<p>In addition, patients with a history of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or thoughts, those patients exhibiting a significant degree of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> prior to commencement of treatment, and young adults are at an increased risk of suicidal thoughts or <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> and should receive careful monitoring during treatment <span class="Italics">[</span><span class="Italics">see <a href="#_2990E853-DB04-CEF8-A9EB-8A0AE0E19015">Warnings and Precautions (5.4)</a></span><span class="Italics">]</span>.  </p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>/behavior, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.  </p>
<p>Prescriptions for lamotrigine tablets should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> have been reported for lamotrigine tablets, some of which have been fatal <span class="Italics">[</span><span class="Italics">see </span><span class="Italics"><a href="#_A9C495AE-60A0-9E9D-843F-318663076BED">Overdosage (10.1)</a></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_676cf395-3aca-7abf-1867-72020e832933"></a><a name="section-5.6"></a><p></p>
<h2><span class="None">5.6 <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> </span></h2>
<p class="First">Therapy with lamotrigine increases the risk of developing <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>. Because of the potential for serious outcomes of untreated <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> due to other causes, patients should also be evaluated for other causes of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and treated as appropriate. </p>
<p>Postmarketing cases of <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> have been reported in pediatric and adult patients taking lamotrigine for various indications. Symptoms upon presentation have included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, altered consciousness, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> were also noted in some cases. Symptoms have been reported to occur within 1 day to one and a half months following the initiation of treatment. In most cases, symptoms were reported to resolve after discontinuation of lamotrigine. Re-exposure resulted in a rapid return of symptoms (from within 30 minutes to 1 day following re-initiation of treatment) that were frequently more severe. Some of the patients treated with lamotrigine who developed <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> had underlying diagnoses of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> or other autoimmune diseases. </p>
<p>Cerebrospinal fluid (CSF) analyzed at the time of clinical presentation in reported cases was characterized by a mild to moderate <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span>, normal glucose levels, and mild to moderate increase in protein. CSF white blood cell count differentials showed a predominance of <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> in a majority of the cases, although a predominance of <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> was reported in approximately one third of the cases. Some patients also had new onset of signs and symptoms of involvement of other organs (predominantly hepatic and renal involvement), which may suggest that in these cases the <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> observed was part of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> <span class="Italics">[see Warnings and Precautions (<a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_4CC26A9A-CDB0-C88E-5FDE-5993FD0695A8"></a><a name="section-5.7"></a><p></p>
<h2> 5.7 Potential Medication Errors<span class="Bold"></span>
</h2>
<p class="First">Medication errors involving lamotrigine tablets have occurred. In particular, the names lamotrigine can be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with the names of other commonly used medications. Medication errors may also occur between the different formulations of lamotrigine tablets. To reduce the potential of medication errors, write and say lamotrigine tablets clearly. Depictions of the lamotrigine tablets can be found in the Medication Guide that accompanies the product to highlight the distinctive markings, colors, and shapes that serve to identify the different presentations of the drug and thus may help reduce the risk of medication errors. To avoid the medication error of using the wrong drug or formulation, patients should be strongly advised to visually inspect their tablets to verify that they are lamotrigine tablets, as well as the correct formulation of lamotrigine, each time they fill their prescription.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_95924841-207B-D6A0-784D-FDC6FEF07711"></a><a name="section-5.8"></a><p></p>
<h2> 5.8 Concomitant Use with Oral Contraceptives </h2>
<p class="First">Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine <span class="Italics">[see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>]</span><span class="Italics">.</span><span class="Bold"> Dosage adjustments will be necessary in most patients who start or stop estrogen-containing oral contraceptives while taking lamotrigine tablets </span><span class="Italics">[see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA"> Dosage and Administration (2.1)</a>]</span><span class="Italics">.</span> During the week of inactive hormone preparation (pill-free week) of oral contraceptive therapy, plasma lamotrigine levels are expected to rise, as much as doubling at the end of the week. Adverse reactions consistent with elevated levels of lamotrigine, such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, could occur. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_F5D88172-4476-75E5-A589-D130B33A634C"></a><a name="section-5.9"></a><p></p>
<h2><span class="None">5.9 <span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal Seizures</span> </span></h2>
<p class="First">As with other AEDs, lamotrigine tablets should not be abruptly discontinued. In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> there is a possibility of increasing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency. In clinical trials in patients with bipolar disorder, 2 patients experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> shortly after abrupt withdrawal of lamotrigine tablets; however, there were confounding factors that may have contributed to the occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in these patients with bipolar disorder. Unless safety concerns require a more rapid withdrawal, the dose of lamotrigine tablets should be tapered over a period of at least 2 weeks (approximately 50% reduction per week)<span class="Italics"> [see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>]</span>.  </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_B3BDBCF7-9020-A308-734F-A1E3B57FAC9F"></a><a name="section-5.10"></a><p></p>
<h2> 5.10 <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status Epilepticus</span> </h2>
<p class="First">Valid estimates of the incidence of treatment-emergent <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> among patients treated with lamotrigine tablets are difficult to obtain because reporters participating in clinical trials did not all employ identical rules for identifying cases. At a minimum, 7 of 2,343 adult patients had episodes that could unequivocally be described as <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>. In addition, a number of reports of variably defined episodes of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> exacerbation (e.g., <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> clusters, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> flurries) were made. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_69D84FD4-AEE7-EA3E-4DFA-2030D2ACC798"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Sudden Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> (SUDEP)
                     </h2>
<p class="First">During the premarketing development of lamotrigine tablets, 20 sudden and unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were recorded among a cohort of 4,700 patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (5,747 patient-years of exposure).  </p>
<p>Some of these could represent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in which the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> was not observed, e.g., at night. This represents an incidence of 0.0035 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (SUDEP) in patients not receiving lamotrigine tablets (ranging from 0.0005 for the general population of patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, to 0.004 for a recently studied clinical trial population similar to that in the clinical development program for lamotrigine tablets, to 0.005 for patients with refractory <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>). Consequently, whether these figures are reassuring or suggest concern depends on the comparability of the populations reported upon with the cohort receiving lamotrigine tablets and the accuracy of the estimates provided. Probably most reassuring is the similarity of estimated SUDEP rates in patients receiving lamotrigine tablets and those receiving other AEDs, chemically unrelated to each other, that underwent clinical testing in similar populations. Importantly, that drug is chemically unrelated to lamotrigine. This evidence suggests, although it certainly does not prove, that the high SUDEP rates reflect population rates, not a drug effect. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_26778CA4-8AD4-5ECC-F40A-BB45A13D4AA8"></a><a name="section-5.12"></a><p></p>
<h2><span class="None">5.12 Addition of Lamotrigine Tablets to a Multidrug Regimen that Includes Valproate </span></h2>
<p class="First">Because valproate reduces the clearance of lamotrigine, the dosage of lamotrigine in the presence of valproate is less than half of that required in its absence <span class="Italics">[</span><span class="Italics"><a href="#_79b34305-d79a-e6b9-a53f-988b4fb3cb80">see Dosage and Administration (2.2</a>, <a href="#_D204D889-DE03-9A38-6B22-12DF857B89AD">2.3</a>, <a href="#_e2903c00-2cc1-ec25-9386-59e8f672a0b5">2.4</a>), <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a></span><span class="Italics">]</span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_64A11F21-55D7-8C5A-B35B-765B39DE7FCE"></a><a name="section-5.13"></a><p></p>
<h2> 5.13 Binding in the Eye and Other Melanin-Containing Tissues </h2>
<p class="First">Because lamotrigine binds to melanin, it could accumulate in melanin-rich tissues over time. This raises the possibility that lamotrigine may cause toxicity in these tissues after extended use. Although ophthalmological testing was performed in 1 controlled clinical trial, the testing was inadequate to exclude subtle effects or injury occurring after long-term exposure. Moreover, the capacity of available tests to detect potentially adverse consequences, if any, of lamotrigine's binding to melanin is unknown <span class="Italics">[</span><span class="Italics">see <a href="#PHARMACODYNAMICS">Clinical Pharmacology (12.2)</a></span><span class="Italics">].</span>  </p>
<p>Accordingly, although there are no specific recommendations for periodic ophthalmological monitoring, prescribers should be aware of the possibility of long-term ophthalmologic effects. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_2DD07307-5038-36E9-6925-FDAA81A7B83E"></a><a name="section-5.14"></a><p></p>
<h2> 5.14 Laboratory Tests </h2>
<p class="First"><span class="Bold Italics">False-Positive Drug Test Results</span></p>
<p>Lamotrigine has been reported to interfere with the assay used in some rapid <span class="product-label-link" type="condition" conceptid="4215138" conceptname="Drug screening test">urine drug screens</span>, which can result in false-positive readings, particularly for phencyclidine (PCP). A more specific analytical method should be used to confirm a positive result.</p>
<p><span class="Bold Italics">Plasma Concentrations of Lamotrigine</span></p>
<p>The value of monitoring plasma concentrations of lamotrigine in patients treated with lamotrigine tablets has not been established. Because of the possible <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between lamotrigine and other drugs, including AEDs (see Table 15), monitoring of the plasma levels of lamotrigine and concomitant drugs may be indicated, particularly during dosage adjustments. In general, clinical judgment should be exercised regarding monitoring of plasma levels of lamotrigine and other drugs and whether or not dosage adjustments are necessary. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described in more detail in the <span class="Italics"><a href="#WARNINGS_AND_PRECAUTIONS">Warnings and Precautions</a></span> section of the label: </p>
<p>• Serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> <span class="Italics">[see <a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">Warnings and Precautions (5.1)</a>] </span></p>
<p>• Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and organ failure <span class="Italics">[see <a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">Warnings and Precautions (5.2)</a>]</span></p>
<p>• <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> <span class="Italics">[see <a href="#_041AE776-AB46-DF3B-06A8-1EA3EC330FCF">Warnings and Precautions (5.3)</a>]</span></p>
<p>• <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> and ideation <span class="Italics">[</span><span class="Italics">see <a href="#_2990E853-DB04-CEF8-A9EB-8A0AE0E19015">Warnings and Precautions (5.4)</a></span><span class="Italics">]</span></p>
<p>• <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> <span class="Italics">[see <a href="#_676cf395-3aca-7abf-1867-72020e832933">Warnings and Precautions (5.6)</a>]</span></p>
<p>• <span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal seizures</span> <span class="Italics">[see <a href="#_F5D88172-4476-75E5-A589-D130B33A634C">Warnings and Precautions (5.9)</a>]</span></p>
<p>• <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status epilepticus</span> <span class="Italics">[see <a href="#_B3BDBCF7-9020-A308-734F-A1E3B57FAC9F">Warnings and Precautions (5.10)</a>]</span></p>
<p>• Sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> <span class="Italics">[see <a href="#_69D84FD4-AEE7-EA3E-4DFA-2030D2ACC798">Warnings and Precautions (5.11)</a>] </span></p>
<div class="Section" data-sectionCode="34084-4">
<a name="_E46D0FC8-F332-5906-7497-1059BE6F286C"></a><a name="section-6.1"></a><p></p>
<h2> 6.1 Clinical Trial Experience  </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.   </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span></p>
<p><span class="Italics">Most Common Adverse Reactions  in All Clinical Trials: Adjunctive Therapy in Adults With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span></p>
<p>The most commonly observed (≥5% for lamotrigine tablets and more common on drug than placebo) adverse reactions seen in association with lamotrigine tablets during adjunctive therapy in adults and not seen at an equivalent frequency among placebo-treated patients were: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were dose related. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> occurred more commonly in patients receiving carbamazepine with lamotrigine tablets than in patients receiving other AEDs with lamotrigine tablets. Clinical data suggest a higher incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, including serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, in patients receiving concomitant valproate than in patients not receiving valproate <span class="Italics">[</span><span class="Italics">see <a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A">Warnings and Precautions (5.1)</a></span><span class="Italics">]</span>.  </p>
<p>Approximately 11% of the 3,378 adult patients who received lamotrigine tablets as adjunctive therapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (3.0%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.8%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.5%).</p>
<p>In a dose-response trial in adults, the rate of discontinuation of lamotrigine tablets for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was dose related. </p>
<p><span class="Italics">Monotherapy in Adults With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span></p>
<p>The most commonly observed (≥5% for lamotrigine tablets and more common on drug than placebo) adverse reactions seen in association with the use of lamotrigine tablets during the monotherapy phase of the controlled trial in adults not seen at an equivalent rate in the control group were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, coordination abnormality, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>. The most commonly observed (≥5% for lamotrigine tablets and more common on drug than placebo) adverse reactions associated with the use of lamotrigine tablets during the conversion to monotherapy (add-on) period, not seen at an equivalent frequency among low-dose valproate-treated patients, were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, coordination abnormality, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.  </p>
<p>Approximately 10% of the 420 adult patients who received lamotrigine tablets as monotherapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (4.5%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3.1%), and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (2.4%).  </p>
<p><span class="Italics">Adjunctive Therapy in Pediatric Patients With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span></p>
<p>The most commonly observed (≥5% for lamotrigine tablets and more common on drug than placebo) adverse reactions seen in association with the use of lamotrigine tablets as adjunctive treatment in pediatric patients aged 2 to 16 years and not seen at an equivalent rate in the control group were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>.  </p>
<p>In 339 patients aged 2 to 16 years with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> of Lennox-Gastaut syndrome, 4.2% of patients on lamotrigine tablets and 2.9% of patients on placebo discontinued due to adverse reactions. The most commonly reported adverse reaction that led to discontinuation of lamotrigine tablets was <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.  </p>
<p>Approximately 11.5% of the 1,081 pediatric patients aged 2 to 16 years who received lamotrigine tablets as adjunctive therapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (4.4%), reaction aggravated (1.7%), and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (0.6%).  </p>
<p><span class="Italics">Controlled Adjunctive Clinical Trials in Adults With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span></p>
<p>Table 8 lists adverse reactions that occurred in adult patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> treated with lamotrigine tablets in placebo-controlled trials. In these studies, either lamotrigine tablets or placebo was added to the patient's current AED therapy.</p>
<p><span class="Bold">Table 8.</span><span class="Bold"> Adverse Reactions in Pooled, Placebo-Controlled Adjunctive Trials in Adult Patients With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span><span class="Sup">a.b</span></span>  </p>
<table frame="border" rules="all" width="80%">
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left" valign="bottom">Body System/Adverse <span class="Bold">Reaction</span>
</th>
<th align="center" valign="bottom"><span class="None">Percent of Patients Receiving Adjunctive Lamotrigine Tablets<br>(n=711)</span></th>
<th align="center" valign="bottom">Percent of Patients Receiving Adjunctive Placebo<br>(n-419)</th>
</tr></thead>
<tbody>
<tr class="First"><td align="left" colspan="3">Body as a whole </td></tr>
<tr>
<td align="left" colspan="1"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td align="center" colspan="1">29</td>
<td align="center" colspan="1">19</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </td>
<td align="center" colspan="1">6</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1">Reaction aggravated (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> exacerbation)</td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Digestive </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" colspan="1">19</td>
<td align="center" colspan="1">10</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" colspan="1">9</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center" colspan="1">6</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">3</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Musculoskeletal </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">0</td>
</tr>
<tr><td align="left" colspan="3">Nervous </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td align="center" colspan="1">38</td>
<td align="center" colspan="1">13</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span> </td>
<td align="center" colspan="1">22</td>
<td align="center" colspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </td>
<td align="center" colspan="1">14</td>
<td align="center" colspan="1">7</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span> </td>
<td align="center" colspan="1">6</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td align="center" colspan="1">6</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">3</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">3</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span> </td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span> </td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1">Speech disorder </td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1">Concentration disturbance </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Respiratory </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> </td>
<td align="center" colspan="1">14</td>
<td align="center" colspan="1">9</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">9</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span> </td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1">6</td>
</tr>
<tr><td align="left" colspan="3">Skin and appendages </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">2</td>
</tr>
<tr><td align="left" colspan="3">Special senses </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span> </td>
<td align="center" colspan="1">28</td>
<td align="center" colspan="1">7</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> </td>
<td align="center" colspan="1">16</td>
<td align="center" colspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1">Vision abnormality </td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Urogenital </td></tr>
<tr>
<td align="left" colspan="1">Female patients only </td>
<td align="center" colspan="1">(n = 365)</td>
<td align="center" colspan="1">(n = 207)</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">1</td>
</tr>
<tr class="Last">
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>  Patients in these adjunctive trials were receiving 1 to 3 of the concomitant antiepileptic drugs carbamazepine, phenytoin, phenobarbital, or primidone in addition to lamotrigine tablets or placebo. Patients may have reported multiple adverse reactions during the trial or at discontinuation; thus, patients may be included in more than 1 category.</p>
<p><span class="Sup">b </span>Patients in these adjunctive trials were receiving 1 to 3 of the concomitant antiepileptic drugs carbamazepine, phenytoin, phenobarbital, or primidone in addition to lamotrigine or placebo. Patients may have reported multiple adverse reactions during the trial or at discontinuation; thus, patients may be included in more than 1 category.</p>
<p>In a randomized, parallel trial comparing placebo with 300 and 500 mg/day of lamotrigine tablets, some of the more common drug-related adverse reactions were dose related (see Table 9). </p>
<table frame="border" rules="all" width="80%">
<caption><span>Table 9. Dose-Related Adverse Reactions from a Randomized, Placebo-Controlled, Adjunctive Trial in Adults with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></caption>
<col align="left" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<tbody class="Headless">
<tr class="First" align="char">
<td align="left" colspan="1"></td>
<td align="center" colspan="3"><span class="Bold">Percent of Patients Experiencing Adverse Reactions</span></td>
</tr>
<tr>
<td align="left" valign="bottom"> Adverse Reaction </td>
<td align="center" valign="bottom"> Placebo<br>(n=73) </td>
<td align="center" valign="bottom"> Lamotrigine Tablets 300 mg<br>(n=71) </td>
<td align="center" valign="bottom"> Lamotrigine Tablets 500 mg<br>(n=72) </td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">28<span class="Sup">a, b</span>
</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">11</td>
<td align="center" colspan="1">25<span class="Sup">a, b</span>
</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span> </td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1">24<span class="Sup">a</span>
</td>
<td align="center" colspan="1">49<span class="Sup"></span><span class="Sup">a, b</span>
</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td align="center" colspan="1">27</td>
<td align="center" colspan="1">31</td>
<td align="center" colspan="1">54<span class="Sup">a, b</span>
</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" colspan="1">11</td>
<td align="center" colspan="1">18</td>
<td align="center" colspan="1">25<span class="Sup">a</span>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">11</td>
<td align="center" colspan="1">18<span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Significantly greater than placebo group (P&lt;0.05).</p>
<p><span class="Sup">b </span>Significantly greater than group receiving lamotrigine tablets 300 mg (P&lt;0.05).</p>
<p>The overall adverse reaction profile for lamotrigine tablets was similar between females and males and was independent of age. Because the largest non-Caucasian racial subgroup was only 6% of patients exposed to lamotrigine tablets in placebo-controlled trials, there are insufficient data to support a statement regarding the distribution of adverse reaction reports by race. Generally, females receiving either lamotrigine tablets as adjunctive therapy or placebo were more likely to report adverse reactions than males. The only adverse reaction for which the reports on lamotrigine tablets were greater than 10% more frequent in females than males (without a corresponding difference by gender on placebo) was <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (difference = 16.5%). There was little difference between females and males in the rates of discontinuation of lamotrigine tablets for individual adverse reactions. </p>
<p><span class="Italics">Controlled Monotherapy Trial in Adults with Partial-Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>Table 10 lists adverse reactions that occurred in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> treated with monotherapy with lamotrigine tablets in a double-blind trial following discontinuation of either concomitant carbamazepine or phenytoin not seen at an equivalent frequency in the control group.</p>
<p></p>
<span class="Bold"><span class="Bold">Table 10. Adverse Reactions in a Controlled Monotherapy Trial in Adult Patients With Partial-Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span><span class="Sup">a,b</span> </span></span><table frame="border" rules="all" width="75%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<tbody class="Headless">
<tr class="First" align="center">
<td align="left"> Body System/Adverse Reaction </td>
<td align="center" rowspan="1"> Percent of Patients Receiving Lamotrigine Tablets as Monotherapy<span class="Sup">c</span><br>(n = 43) </td>
<td align="center" rowspan="1"> Percent of Patients Receiving Low-Dose Valproate Monotherapy<span class="Sup">d</span><br>(n = 44) </td>
</tr>
<tr><td align="left" colspan="3">Body as a whole </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">2</td>
</tr>
<tr><td align="left" colspan="3">Digestive </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" colspan="1">9</td>
<td align="center" colspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">2</td>
</tr>
<tr><td align="left" colspan="3">Metabolic and nutritional </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">2</td>
</tr>
<tr><td align="left" colspan="3">Nervous </td></tr>
<tr>
<td align="left" colspan="1">Coordination abnormality</td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">2</td>
</tr>
<tr><td align="left" colspan="3">Respiratory </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1">Urogenital (female patients only)</td>
<td align="center" colspan="1">(n = 21)</td>
<td align="center" colspan="1">(n = 28)</td>
</tr>
<tr class="Last">
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">0</td>
</tr>
</tbody>
</table>
<br><span class="Sup"></span><p><span class="Sup">a </span>Adverse reactions in at least 5% of patients treated with LAMICTAL and at a greater incidence than valproate-treated patients.</p>
<p><span class="Sup">b </span>Patients in this trial were converted to lamotrigine or valproate monotherapy from adjunctive therapy with carbamazepine or phenytoin. Patients may have reported multiple adverse reactions during the trial; thus, patients may be included in more than 1 category.</p>
<p><span class="Sup">c</span>Up to 500 mg/day.</p>
<p><span class="Sup">d </span>1,000 mg/day. </p>
<p>Adverse reactions that occurred with a frequency of less than 5% and greater than 2% of patients receiving lamotrigine tablets and numerically more frequent than placebo were: </p>
<p><span class="Italics">Body as a Whole:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p><span class="Italics">Digestive:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
<p><span class="Italics">Metabolic and Nutritional:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>.</p>
<p><span class="Italics">Nervous System:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, libido increase, decreased reflexes, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">increased reflexes</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>.</p>
<p><span class="Italics">Respiratory: </span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="Italics">Skin and Appendages:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p><span class="Italics">Special Senses: </span> Vision abnormality.  </p>
<p><span class="Italics">Incidence in Controlled Adjunctive Trials in Pediatric Patients With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></p>
<p>Table 11 lists adverse reactions that occurred in 339 pediatric patients with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> of Lennox-Gastaut syndrome who received lamotrigine tablets up to 15 mg/kg/day or a maximum of 750 mg/day.</p>
<p><span class="Bold">Table 11. Adverse Reactions in Pooled, Placebo-Controlled Adjunctive Trials in Pediatric Patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span><span class="Sup">a</span> </span></p>
<table frame="border" rules="all" width="80%">
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<tbody class="Headless">
<tr class="First" align="center">
<td align="left" valign="bottom"> Body System/Adverse Reaction </td>
<td align="center" valign="bottom"> Percent of Patients Receiving Lamotrigine Tablets<br>(n = 168) </td>
<td align="center" valign="bottom"> Percent of Patients Receiving Placebo<br>(n = 171) </td>
</tr>
<tr><td align="left" colspan="3">Body as a whole</td></tr>
<tr align="center">
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
<td align="center" colspan="1">20</td>
<td align="center" colspan="1">17</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </td>
<td align="center" colspan="1">15</td>
<td align="center" colspan="1">14</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span> </td>
<td align="center" colspan="1">14</td>
<td align="center" colspan="1">12</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1">Facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">0</td>
</tr>
<tr><td align="left" colspan="3">Cardiovascular</td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Digestive</td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" colspan="1">20</td>
<td align="center" colspan="1">16</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center" colspan="1">11</td>
<td align="center" colspan="1">9</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Hemic and lymphatic</td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Metabolic and nutritional</td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">0</td>
</tr>
<tr><td align="left" colspan="3">Nervous system</td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" colspan="1">17</td>
<td align="center" colspan="1">15</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td align="center" colspan="1">14</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span> </td>
<td align="center" colspan="1">11</td>
<td align="center" colspan="1">3</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional lability</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1">Gait abnormality </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1">Thinking abnormality</td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Respiratory</td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td align="center" colspan="1">14</td>
<td align="center" colspan="1">11</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1">Increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Skin </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td align="center" colspan="1">14</td>
<td align="center" colspan="1">12</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">1</td>
</tr>
<tr><td align="left" colspan="3">Special senses</td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span> </td>
<td align="center" colspan="1" rowspan="1">5</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1">Visual abnormality</td>
<td align="center" colspan="1">2</td>
<td align="center" colspan="1">0</td>
</tr>
<tr><td align="left" colspan="3">Urogenital </td></tr>
<tr><td align="left" colspan="3">Male and female patients</td></tr>
<tr class="Last">
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">0</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Adverse reactions that occurred in at least 2% of patients treated with lamotrigine and at a greater incidence than placebo.</p>
<p><span class="Bold Italics">Bipolar Disorder </span></p>
<p>The most common adverse reactions seen in association with the use of lamotrigine as monotherapy (100 to 400 mg/day) in adult patients (aged 18 years and older) with bipolar disorder in the 2 double-blind, placebo-controlled trials of 18 months’ duration are included in Table 12. Adverse reactions that occurred in at least 5% of patients and were numerically more frequent during the dose-escalation phase of lamotrigine in these trials (when patients may have been receiving concomitant medications) compared with the monotherapy phase were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (25%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (11%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (10%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8%), dream abnormality (6%), and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (6%). </p>
<p>During the monotherapy phase of the double-blind, placebo-controlled trials of 18 months’ duration, 13% of 227 patients who received lamotrigine tablets (100 to 400 mg/day), 16% of 190 patients who received placebo, and 23% of 166 patients who received lithium discontinued therapy because of an adverse reaction. The adverse reactions which most commonly led to discontinuation of lamotrigine tablets were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (3%) and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>/mixed mood adverse reactions (2%). Approximately 16% of 2,401 patients who received lamotrigine tablets (50 to 500 mg/day) for bipolar disorder in premarketing trials discontinued therapy because of an adverse reaction,  most commonly due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (5%) and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>/mixed mood adverse reactions (2%). </p>
<p>The overall adverse reaction profile for lamotrigine tablets was similar between females and males, between elderly and nonelderly patients, and among racial groups.</p>
<p><span class="Bold">Table 12. Adverse Reactions in 2 Placebo-Controlled Trials in Adult Patients with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span><span class="Sup">a,b</span></span></p>
<table border="" frame="border" rules="all" width="80%">
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<tbody class="Headless">
<tr class="First" align="center">
<td align="left" valign="bottom"> Body System/ Adverse Reaction </td>
<td align="center" valign="bottom"> Percent of Patients Receiving Lamotrigine Tablets<br>(n = 227) </td>
<td align="center" valign="bottom"> Percent of Patients Receiving Placebo<br>(n = 190) </td>
</tr>
<tr><td align="left" colspan="3">General </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> </td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td align="center" colspan="1">6</td>
<td align="center" colspan="1">3</td>
</tr>
<tr><td align="left" colspan="3">Digestive </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" colspan="1">14</td>
<td align="center" colspan="1">11</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">2</td>
</tr>
<tr><td align="left" colspan="3">Nervous System </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" colspan="1">9</td>
<td align="center" colspan="1">7</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Xerostomia</span> (<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>) </td>
<td align="center" colspan="1">6</td>
<td align="center" colspan="1">4</td>
</tr>
<tr><td align="left" colspan="3">Respiratory </td></tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> </td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1">Exacerbation of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">3</td>
</tr>
<tr>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td align="center" colspan="1">5</td>
<td align="center" colspan="1">4</td>
</tr>
<tr><td align="left" colspan="3">Skin </td></tr>
<tr class="Last">
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (nonserious)<span class="Sup">c</span>
</td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">5</td>
</tr>
</tbody>
</table>
<p></p>
<p><span class="Sup">a</span> Adverse reactions that occurred in at least 5% of patients treated with lamotrigine and at a greater incidence than placebo.</p>
<p><span class="Sup">b</span> Patients in these trials were converted to lamotrigine tablets (100 to 400 mg/day) or placebo monotherapy from add-on therapy with other psychotropic medications. Patients may have reported multiple adverse reactions during the trial; thus, patients may be included in more than 1 category.</p>
<p><span class="Sup">c </span>In the overall bipolar and other mood disorders clinical trials, the rate of serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was 0.08% (1 of 1,233) of adult patients who received lamotrigine tablets as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received lamotrigine tablets as adjunctive therapy  <span class="Italics">[see <a href="#_1B65B547-84BD-90EF-0CB2-F30527EDA77A"> Warnings and Precautions (5.1)</a>]</span>. </p>
<p> Other reactions that occurred in 5% or more patients but equally or more frequently in the placebo group included: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>.</p>
<p>Adverse reactions that occurred with a frequency of less than 5% and greater than 1% of patients receiving lamotrigine tablets and numerically more frequent than placebo were: </p>
<p><span class="Italics">General:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>.</p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span>.</p>
<p><span class="Italics">Digestive:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>. </p>
<p><span class="Italics">Metabolic and Nutritional:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. </p>
<p><span class="Italics">Musculoskeletal:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Italics">Nervous System:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4290260" conceptname="Dyspraxia">dyspraxia</span>, abnormal thoughts, dream abnormality, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.</p>
<p><span class="Italics">Respiratory:</span><span class="Bold Italics"></span> <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>.</p>
<p><span class="Italics">Urogenital: </span><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>.</p>
<p><span class="Bold Italics">Adverse Reactions Following Abrupt Discontinuation</span></p>
<p>In the 2 maintenance trials, there was no increase in the incidence, severity, or type of adverse reactions in patients with bipolar disorder after abruptly terminating therapy with lamotrigine tablets. In clinical trials in patients with bipolar disorder, 2 patients experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> shortly after abrupt withdrawal of lamotrigine tablets. However, there were confounding factors that may have contributed to the occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in these patients with bipolar disorder <span class="Italics">[</span><span class="Italics">see <a href="#_F5D88172-4476-75E5-A589-D130B33A634C">Warnings and Precautions (5.9)</a></span><span class="Italics">]</span>.  </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span>/Mixed Episodes</span></p>
<p>During the double-blind, placebo-controlled clinical trials in <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> in which patients were converted to monotherapy with lamotrigine tablets (100 to 400 mg/day) from other psychotropic medications and followed for up to 18 months, the rates of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or hypomanic or mixed mood episodes reported as adverse reactions were 5% for patients treated with lamotrigine tablets (n = 227), 4% for patients treated with lithium (n = 166), and 7% for patients treated with placebo (n = 190). In all bipolar controlled trials combined, adverse reactions of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (including <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> and mixed mood episodes) were reported in 5% of patients treated with lamotrigine tablets (n = 956), 3% of patients treated with lithium (n = 280), and 4% of patients treated with placebo (n = 803). </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_9E8D641F-002A-3B21-50FD-F9081E89292F"></a><a name="section-6.2"></a><p></p>
<h2> 6.2 Other Adverse Reactions Observed in All Clinical Trials </h2>
<p class="First">Lamotrigine tablets have been administered to 6,694 individuals for whom complete adverse reaction data was captured during all clinical trials, only some of which were placebo controlled. During these trials, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of adverse reactions were grouped into a smaller number of standardized categories using modified COSTART dictionary terminology. The frequencies presented represent the proportion of the 6,694 individuals exposed to lamotrigine tablets who experienced an event of the type cited on at least 1 occasion while receiving lamotrigine tablets. All reported adverse reactions are included except those already listed in the previous tables or elsewhere in the labeling, those too general to be informative, and those not reasonably associated with the use of the drug.  </p>
<p>Adverse reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: <span class="Italics">frequent</span> adverse reactions are defined as those occurring in at least 1/100 patients; <span class="Italics">infrequent</span> adverse reactions are those occurring in 1/100 to 1/1,000 patients; <span class="Italics">rare</span> adverse reactions are those occurring in fewer than 1/1,000 patients. </p>
<p><span class="Bold Italics">Body as a Whole: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. </p>
<p><span class="Bold Italics">Cardiovascular System: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, vasodilation. </p>
<p><span class="Bold Italics">Dermatological: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="4041510" conceptname="Skin hypopigmented">leukoderma</span>, multiforme <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechial rash</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustular rash</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>.</p>
<p><span class="Bold Italics">Digestive System: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>. <span class="Italics">Rare: </span> <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>, gum <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4216673" conceptname="Hemorrhagic colitis">hemorrhagic colitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>.</p>
<p><span class="Bold Italics">Endocrine System: </span><span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Goiter</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
<p><span class="Bold Italics">Hematologic and Lymphatic System: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, fibrin decrease, fibrinogen decrease, <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="4308125" conceptname="Macrocytic anemia">macrocytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. </p>
<p><span class="Bold Italics">Metabolic and Nutritional Disorders: </span><span class="Italics">Infrequent: </span>Aspartate transaminase increased. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4010023" conceptname="Alcohol intolerance">Alcohol intolerance</span>, alkaline phosphatase increase, alanine transaminase increase, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, general <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, gamma glutamyl transpeptidase increase, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. </p>
<p><span class="Bold Italics">Musculoskeletal System: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">Bursitis</span>, <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle atrophy</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span>, <span class="product-label-link" type="condition" conceptid="4164222" conceptname="Tendon contracture">tendinous contracture</span>. </p>
<p><span class="Bold Italics">Nervous System: </span><span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, memory decrease, mind racing, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">Choreoathetosis</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, faintness, <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal convulsions</span>, <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">hemiplegia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperalgesia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">manic depression</span> reaction, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>.</p>
<p><span class="Bold Italics">Respiratory System: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawn</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccup</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>. </p>
<p><span class="Bold Italics">Special Senses: </span><span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">Abnormality of accommodation</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> disorder, <span class="product-label-link" type="condition" conceptid="4081310" conceptname="Movement of visual image - finding">oscillopsia</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="4329707" conceptname="Strabismus">strabismus</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>. </p>
<p><span class="Bold Italics">Urogenital System: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>. <span class="Italics">Rare</span>: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute kidney failure</span>, <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, <span class="product-label-link" type="condition" conceptid="4153106" conceptname="Abscess of breast">breast abscess</span>, breast neoplasm, creatinine increase, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4150043" conceptname="Epididymitis">epididymitis</span>, female lactation, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">kidney pain</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>. </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_BCA81295-DD08-EC43-6453-F1DA752BB7CD"></a><a name="section-6.3"></a><p></p>
<h2><span class="None">6.3 Postmarketing Experience </span></h2>
<p class="First">The following adverse events (not listed above in clinical trials or other sections of the prescribing information) have been identified during postapproval use of lamotrigine tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.   </p>
<p><span class="Bold Italics">Blood and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>,  <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> not associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> disorder. </p>
<p><span class="Bold Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span>.</p>
<p><span class="Bold Italics">Hepatobiliary Tract and Pancreas: </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>.</p>
<p><span class="Bold Italics">Immunologic: </span>Lupus-like reaction, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Bold Italics">Lower Respiratory: </span><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>.</p>
<p><span class="Bold Italics">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> has been observed in patients experiencing <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
<p><span class="Bold Italics"><span class="Bold">Nervous System</span>: </span><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span>, exacerbation of Parkinsonian symptoms in patients with pre-existing Parkinson’s disease, <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span>. </p>
<p><span class="Bold Italics">Non-site Specific: </span>Progressive <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Significant drug interactions with lamotrigine are summarized in this section. Additional details of these drug interaction studies are provided in the Clinical Pharmacology section <span class="Italics">[see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>].</span> </p>
<table frame="border" rules="all" width="80%">
<caption><span>Table 13. Established and Other Potentially Significant Drug Interactions</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="35%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="bottom">Concomitant Drug</td>
<td align="left" valign="bottom">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="left" valign="bottom">Clinical Comment</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="colgroup">Estrogen-containing oral contraceptive preparations containing 30 mcg. ethinylestradiol and 150 mcg levonorgestrel </td>
<td align="left" colspan="1">↓ lamotrigine <br>↓levonorgestrel </td>
<td align="left" colspan="1">Decreased lamotrigine concentrations approximately 50%. Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr>
<td align="left" colspan="1">Carbamazepine (CBZ) and CBZ epoxide </td>
<td align="left" colspan="1">↓ lamotrigine<br>? Carbamazepine epoxide </td>
<td align="left" colspan="1">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.  May increase CBZ epoxide levels. </td>
</tr>
<tr>
<td align="left" colspan="1">Lopinavir/ritonavir</td>
<td align="left" colspan="1">↓ lamotrigine</td>
<td align="left" colspan="1">Decreased lamotrigine concentration approximately 50%.</td>
</tr>
<tr>
<td align="left" colspan="1">Atazanavir/ritonavir</td>
<td align="left" colspan="1">↓ lamotrigine</td>
<td align="left" colspan="1">Decreased lamotrigine AUC approximately 32%</td>
</tr>
<tr>
<td align="left" colspan="1">Phenobarbital/Primidone </td>
<td align="left" colspan="1">↓ lamotrigine </td>
<td align="left" colspan="1">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr>
<td align="left" colspan="1">Phenytoin (PHT)</td>
<td align="left" colspan="1">↓ lamotrigine </td>
<td align="left" colspan="1">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr>
<td align="left" colspan="1">Rifampin </td>
<td align="left" colspan="1">↓ lamotrigine </td>
<td align="left" colspan="1">Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Valproate</td>
<td align="left" colspan="1" valign="top">↑ lamotrigine<br><br>? valproate</td>
<td align="left" colspan="1">Increased lamotrigine concentrations slightly more than 2-fold. <br><br>There are conflicting study results regarding effect of lamotrigine on valproate concentrations: 1) a mean 25% decrease in valproate concentrations in healthy volunteers, 2) no change in valproate concentrations in controlled clinical trials in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. </td>
</tr>
</tbody>
</table>
<br><p>↓=Decreased (induces lamotrigine glucuronidation). </p>
<p>↑=Increased (inhibits lamotrigine glucuronidation). </p>
<p>?=Conflicting data. </p>
<p><span class="Bold Underline">Effect of Lamotrigine on Organic Cationic Transporter 2 Substrates</span><span class="Bold"></span></p>
<p>Lamotrigine is an inhibitor of renal tubular secretion via organic cationic transporter 2 (OCT2) proteins <span class="Italics">[see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>].</span> This may result in increased plasma levels of certain drugs that are substantially excreted via this route. Coadministration of lamotrigine with OCT2 substrates with a narrow therapeutic index (e.g., dofetilide) is not recommended. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="USE_IN_SPECIFIC_POPULATIONS"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42228-7">
<a name="PREGNANCY"></a><a name="section-8.1"></a><p></p>
<h2><span class="None">8.1 Pregnancy </span></h2>
<p class="First"><span class="Bold Italics"></span>As with other AEDs, physiological changes during pregnancy may affect lamotrigine concentrations and/or therapeutic effect. There have been reports of decreased lamotrigine concentrations during pregnancy and restoration of pre-partum concentrations after delivery. Dosage adjustments may be necessary to maintain clinical response.    </p>
<p><span class="Bold Italics"><span class="Bold Italics">Pregnancy Category C</span></span></p>
<p><span class="Bold Italics"></span>There are no adequate and well-controlled studies in pregnant women. In animal studies, lamotrigine was developmentally toxic at doses lower than those administered clinically. Lamotrigine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. When lamotrigine was administered to pregnant mice, rats, or rabbits during the period of organogenesis (oral doses of up to 125, 25, and 30 mg/kg, respectively), reduced fetal body weight and increased incidences of fetal skeletal variations were seen in mice and rats at doses that were also maternally toxic. The no-effect doses for embryofetal developmental toxicity in mice, rats, and rabbits (75, 6.25, and 30 mg/kg, respectively) are similar to (mice and rabbits) or less than (rats) the human dose of 400 mg/day on a body surface area (mg/m2) basis.</p>
<p>In a study in which pregnant rats were administered lamotrigine (oral doses of 5 or 25 mg/kg) during the period of organogenesis and offspring were evaluated postnatally, behavioral abnormalities were observed in exposed offspring at both doses. The lowest effect dose for developmental <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> in rats is less than the human dose of 400 mg/day on a mg/m<span class="Sup">2</span> basis. Maternal toxicity was observed at the higher dose tested.</p>
<p>When pregnant rats were administered lamotrigine (oral doses of 5, 10, or 20 mg/kg) during the latter part of gestation, increased offspring mortality (including <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>) was seen at all doses. The lowest effect dose for peri/postnatal developmental toxicity in rats is less than the human dose of 400 mg/day on a mg/m<span class="Sup">2</span> basis. Maternal toxicity was observed at the 2 highest doses tested.</p>
<p>Lamotrigine decreases fetal folate concentrations in rat, an effect known to be associated with adverse pregnancy outcomes in animals and humans.</p>
<p><span class="Bold Italics">Pregnancy Registry</span></p>
<p>To provide information regarding the effects of <span class="Italics">in utero</span> exposure to lamotrigine tablets, physicians are advised to recommend that pregnant patients taking lamotrigine tablets enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334 and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.  </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LABOR_AND_DELIVERY"></a><a name="section-8.2"></a><p></p>
<h2><span class="None">8.2 Labor and Delivery </span></h2>
<p class="First">The effect of lamotrigine on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="NURSING_MOTHERS"></a><a name="section-8.3"></a><p></p>
<h2><span class="None">8.3 Nursing Mothers </span></h2>
<p class="First">Lamotrigine is present in milk from lactating women taking lamotrigine. Data from multiple small studies indicate that lamotrigine plasma levels in human milk-fed infants have been reported to be as high as 50% of the maternal serum levels. Neonates and young infants are at risk for high serum levels because maternal serum and milk levels can rise to high levels postpartum if lamotrigine dosage has been increased during pregnancy but not later reduced to the pre-pregnancy dosage. Lamotrigine exposure is further increased due to the immaturity of the infant glucuronidation capacity needed for drug clearance. Events including <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and poor sucking have been reported in infants who have been human milk-fed by mothers using lamotrigine; whether or not these events were caused by lamotrigine is unknown. Human milk-fed infants should be closely monitored for adverse events resulting from lamotrigine. Measurement of infant serum levels should be performed to rule out toxicity if concerns arise. Human milk-feeding should be discontinued in infants with lamotrigine toxicity. Caution should be exercised when lamotrigine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="PEDIATRIC_USE"></a><a name="section-8.4"></a><p></p>
<h2><span class="None">8.4 Pediatric Use </span></h2>
<p class="First">Lamotrigine is indicated for adjunctive therapy in patients aged 2 years and older for partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, the generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> of Lennox-Gastaut syndrome, and PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.  </p>
<p>Safety and efficacy of lamotrigine tablets, used as adjunctive treatment for partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were not demonstrated in a small, randomized, double-blind, placebo-controlled withdrawal trial in very young pediatric patients (aged 1 to 24 months). Lamotrigine tablets were associated with an increased risk for infectious adverse reactions (lamotrigine tablets 37%, placebo 5%), and respiratory adverse reactions (lamotrigine tablets 26%, placebo 5%). Infectious adverse reactions included <span class="product-label-link" type="condition" conceptid="4165112" conceptname="Bronchiolitis">bronchiolitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span>, <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span>, <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>. Respiratory adverse reactions included <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
<p>Safety and effectiveness in patients younger than 18 years with bipolar disorder have not been established.</p>
<p>In a juvenile animal study in which lamotrigine (oral doses of 5, 15, or 30 mg/kg) was administered to young rats (postnatal days 7 to 62), decreased viability and growth were seen at the highest dose tested and long-term behavioral abnormalities (decreased locomotor activity, increased reactivity, and learning deficits in animals tested as adults) were observed at the 2 highest doses. The no-effect dose for adverse effects on neurobehavioral development is less than the human dose of 400 mg/day on a mg/m<span class="Sup">2 </span>basis.  </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="GERIATRIC_USE"></a><a name="section-8.5"></a><p></p>
<h2><span class="None">8.5 Geriatric Use </span></h2>
<p class="First">Clinical trials of lamotrigine tablets for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and bipolar disorder did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients or exhibit a different safety profile than that of younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="_8026C201-30A0-9505-7E08-04E7CFCBA83D"></a><a name="section-8.6"></a><p></p>
<h2><span class="None">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></h2>
<p class="First">Experience in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is limited. Based on a clinical pharmacology study in 24 subjects with mild, moderate, and severe liver impairment <span class="Italics">[see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>]</span>, the following general recommendations can be made. No dosage adjustment is needed in patients with mild liver impairment. Initial, escalation, and maintenance doses should generally be reduced by approximately 25% in patients with moderate and severe liver impairment without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> and 50% in patients with severe liver impairment with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>. Escalation and maintenance doses may be adjusted according to clinical response <span class="Italics">[see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="_C91873C0-ADD1-677A-C099-D730DE9A4549"></a><a name="section-8.7"></a><p></p>
<h2><span class="None">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></h2>
<p class="First">Lamotrigine is metabolized mainly by glucuronic acid conjugation, with the majority of the metabolites being recovered in the urine. In a small study comparing a single dose of lamotrigine in subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with healthy volunteers, the plasma half-life of lamotrigine was approximately twice as long in the subjects with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> <span class="Italics">[see <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>]</span>.  </p>
<p>Initial doses of lamotrigine tablets should be based on patients' AED regimens; reduced maintenance doses may be effective for patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Few patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have been evaluated during chronic treatment with lamotrigine. Because there is inadequate experience in this population, lamotrigine tablets should be used with caution in these patients <span class="Italics">[see <a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a>]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OVERDOSAGE"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34088-5">
<a name="_A9C495AE-60A0-9E9D-843F-318663076BED"></a><a name="section-9.1"></a><p></p>
<h2><span class="None">10.1 Human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> Experience </span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> involving quantities up to 15 g have been reported for lamotrigine tablets, some of which have been fatal. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> has resulted in <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (including tonic <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>), decreased level of consciousness, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and intraventricular conduction delay. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="_515BD0CB-991E-49F3-6004-C7A5B8AACC18"></a><a name="section-9.2"></a><p></p>
<h2> 10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> </h2>
<p class="First">There are no specific antidotes for lamotrigine. Following a suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, hospitalization of the patient is advised. General supportive care is indicated, including frequent monitoring of vital signs and close observation of the patient. If indicated, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> should be induced; usual precautions should be taken to protect the airway. It should be kept in mind that immediate-release lamotrigine is rapidly absorbed <span class="Italics">[see </span><span class="Italics"><a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood. In 6 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> patients, about 20% of the amount of lamotrigine in the body was removed by hemodialysis during a 4-hour session. A Poison Control Center should be contacted for information on the management of overdosage of lamotrigine tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Lamotrigine, an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Its chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-<span class="Italics">as</span>-triazine, its molecular formula is C<span class="Sub">9</span>H<span class="Sub">7</span>N<span class="Sub">5</span>Cl<span class="Sub">2</span>, and its molecular weight is 256.09. Lamotrigine is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> cream-colored powder and has a pK<span class="Sub">a </span>of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural formula is: </p>
<p><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=Structure.jpg"></p>
<p>Lamotrigine tablets are supplied for oral administration as 25 mg (white), 100 mg (peach), 150 mg (cream), and 200 mg (blue) tablets. Each tablet contains the labeled amount of lamotrigine and the following inactive ingredients: magnesium stearate; microcrystalline cellulose; colloidal silicon dioxide; sodium starch glycolate; Sunset Yellow Aluminum Lake (100 mg tablet only); ferric oxide, yellow (150 mg tablet only); and Indigotine Al Lake (200 mg tablet only). </p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43679-0">
<a name="MECHANISM_OF_ACTION"></a><a name="section-11.1"></a><p></p>
<h2><span class="None">12.1 Mechanism of Action </span></h2>
<p class="First">The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, however, is not known.  </p>
<p>One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. <span class="Italics">In vitro</span> pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). </p>
<p><span class="Bold Italics">Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity</span></p>
<p>Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC<span class="Sub">50</span> for lamotrigine effects on NMDA-induced currents (in the presence of 3 mcM of glycine) in cultured hippocampal neurons exceeded 100 mcM.  </p>
<p>The mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="PHARMACODYNAMICS"></a><a name="section-11.2"></a><p></p>
<h2> 12.2 Pharmacodynamics </h2>
<p class="First"><span class="Bold Italics">Folate Metabolism</span></p>
<p><span class="Italics">In vitro</span>, lamotrigine inhibited dihydrofolate reductase, the enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate. Inhibition of this enzyme may interfere with the biosynthesis of nucleic acids and proteins. When oral daily doses of lamotrigine were given to pregnant rats during organogenesis, fetal, placental, and maternal folate concentrations were reduced. Significantly reduced concentrations of folate are associated with teratogenesis <span class="Italics">[see <a href="#PREGNANCY">Use in Specific Populations (8.1)</a>]</span>. Folate concentrations were also reduced in male rats given repeated oral doses of lamotrigine. Reduced concentrations were partially returned to normal when supplemented with folinic acid.  </p>
<p><span class="Bold Italics">Accumulation in Kidneys</span></p>
<p>Lamotrigine accumulated in the kidney of the male rat, causing chronic progressive <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and mineralization. These findings are attributed to α-2 microglobulin, a species- and sex-specific protein that has not been detected in humans or other animal species. </p>
<p><span class="Bold Italics">Melanin Binding</span></p>
<p>Lamotrigine binds to melanin-containing tissues, e.g., in the eye and pigmented skin. It has been found in the uveal tract up to 52 weeks after a single dose in rodents. </p>
<p><span class="Bold Italics">Cardiovascular</span></p>
<p>In dogs, lamotrigine is extensively metabolized to a 2-N-methyl metabolite. This metabolite causes dose-dependent prolongation of the PR interval, widening of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span>, and, at higher doses, complete AV conduction block. Similar cardiovascular effects are not anticipated in humans because only trace amounts of the 2-N-methyl metabolite (&lt;0.6% of lamotrigine dose) have been found in human urine  <span class="Italics">[</span><span class="Italics">see <a href="#PHARMACOKINETICS"> Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. However, it is conceivable that plasma concentrations of this metabolite could be increased in patients with a reduced capacity to glucuronidate lamotrigine (e.g., in patients with liver disease, patients taking concomitant medications that inhibit glucuronidation).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="PHARMACOKINETICS"></a><a name="section-11.3"></a><p></p>
<h2><span class="None">12.3 Pharmacokinetics </span></h2>
<p class="First">The pharmacokinetics of lamotrigine have been studied in subjects with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, healthy young and elderly volunteers, and volunteers with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>. Lamotrigine pharmacokinetic parameters for adult and pediatric subjects and healthy normal volunteers are summarized in Tables 14 and 16.       </p>
<table frame="border" rules="all" width="100%">
<caption><span>Table 14. Mean<span class="Sup"></span><span class="Sup"></span> Pharmacokinetic Parameters<span class="Sup">a</span> in Healthy Volunteers and Adult Subjects With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="15%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="bottom"> Adult Study Population </td>
<td align="center" valign="bottom"> Number of Subjects </td>
<td align="center" valign="bottom"> T<span class="Sub">max</span>: Time of Maximum Plasma Concentration (h) </td>
<td align="center" valign="bottom"> t<span class="Sub">½</span>: Elimination Half-life (h) </td>
<td align="center" valign="bottom"> Cl/F: Apparent Plasma Clearance (mL/min/kg) </td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Healthy volunteers taking no other medications:</span></td></tr>
<tr>
<td align="left" colspan="1">Single-dose Lamotrigine </td>
<td align="center" colspan="1">179</td>
<td align="center" colspan="1">2.2</td>
<td align="center" colspan="1">32.8</td>
<td align="center" colspan="1">0.44</td>
</tr>
<tr>
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(0.25-12.0)</td>
<td align="center" colspan="1">(14.0-103.0)</td>
<td align="center" colspan="1">0.12-1.10)</td>
</tr>
<tr>
<td align="left" colspan="1">Multiple-dose Lamotrigine </td>
<td align="center" colspan="1">36</td>
<td align="center" colspan="1">1.7</td>
<td align="center" colspan="1">25.4</td>
<td align="center" colspan="1">0.58</td>
</tr>
<tr>
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(0.5-4.0)</td>
<td align="center" colspan="1">(11.6-61.6)</td>
<td align="center" colspan="1">(0.24-1.15)</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Healthy volunteers taking valproate:</span></td></tr>
<tr>
<td align="left" colspan="1">Single-dose Lamotrigine </td>
<td align="center" colspan="1">6</td>
<td align="center" colspan="1">1.8</td>
<td align="center" colspan="1">48.3</td>
<td align="center" colspan="1">0.30</td>
</tr>
<tr>
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(1.0-4.0)</td>
<td align="center" colspan="1">(31.5-88.6)</td>
<td align="center" colspan="1">(0.14-0.42)</td>
</tr>
<tr>
<td align="left" colspan="1">Multiple-dose Lamotrigine </td>
<td align="center" colspan="1">18</td>
<td align="center" colspan="1">1.9</td>
<td align="center" colspan="1">70.3</td>
<td align="center" colspan="1">0.18</td>
</tr>
<tr>
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(0.5-3.5)</td>
<td align="center" colspan="1">(41.9-113.5)</td>
<td align="center" colspan="1">(0.12-0.33)</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold"><span class="Bold">Subjects</span> with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> taking valproate only: </span></td></tr>
<tr>
<td align="left" colspan="1">Single-dose Lamotrigine </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1">4.8</td>
<td align="center" colspan="1">58.8</td>
<td align="center" colspan="1">0.28</td>
</tr>
<tr>
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(1.8-8.4)</td>
<td align="center" colspan="1">(30.5-88.8)</td>
<td align="center" colspan="1">(0.16-0.40)</td>
</tr>
<tr><td align="left" colspan="5">
<span class="Bold"><span class="Bold">Subjects</span> with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> taking carbamazepine, phenytoin,<br>phenobarbital, or primidone</span><span class="Sup">b</span><span class="Bold"> plus valproate: </span>
</td></tr>
<tr>
<td align="left" colspan="1">Single-dose Lamotrigine </td>
<td align="center" colspan="1">25</td>
<td align="center" colspan="1">3.8</td>
<td align="center" colspan="1">27.2</td>
<td align="center" colspan="1">0.53</td>
</tr>
<tr>
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(1.0-10.0)</td>
<td align="center" colspan="1">(11.2-51.6)</td>
<td align="center" colspan="1">(0.27-1.04)</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold"><span class="Bold">Subjects</span> with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> taking carbamazepine, phenytoin,<br>phenobarbital, or primidone: </span></td></tr>
<tr>
<td align="left" colspan="1">Single-dose Lamotrigine </td>
<td align="center" colspan="1">24</td>
<td align="center" colspan="1">2.3</td>
<td align="center" colspan="1">14.4</td>
<td align="center" colspan="1">1.10</td>
</tr>
<tr>
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">((0.5-5.0)</td>
<td align="center" colspan="1">(6.4-30.4)</td>
<td align="center" colspan="1">(0.51-2.22)</td>
</tr>
<tr>
<td align="left" colspan="1">Multiple-dose Lamotrigine </td>
<td align="center" colspan="1">17</td>
<td align="center" colspan="1">2.0</td>
<td align="center" colspan="1">12.6</td>
<td align="center" colspan="1">1.21</td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Tablets</td>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(0.75-5.93)</td>
<td align="center" colspan="1">(7.5-23.1)</td>
<td align="center" colspan="1">(0.66-1.82)</td>
</tr>
</tbody>
</table>
<span class="Bold"></span><p><span class="Bold Italics"></span><span class="None"><span class="Sup">a</span> The majority of parameter means determined in each study had coefficients of variation between 20% and 40% for half-life and Cl/F and between 30% and 70% for T<span class="Sub">max</span>. The overall mean values were calculated from individual study means that were weighted based on the number of volunteers/<span class="None">subjects</span> in each study. The numbers in parentheses below each parameter mean represent the range of individual volunteer/subject values across studies.</span></p>
<p><span class="None"><span class="Sup">b </span>Carbamazepine, phenytoin, phenobarbital, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and other drugs, such as rifampin and protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir, that induce lamotrigine glucuronidation have also been shown to increase the apparent clearance of lamotrigine </span><span class="Italics">[see <a href="#DRUG_INTERACTIONS"> Drug Interactions (7)</a>].</span></p>
<p><span class="Bold Italics">Absorption</span></p>
<p>Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%). The bioavailability is not affected by food. Peak plasma concentrations occur anywhere from 1.4 to 4.8 hours following drug administration. The lamotrigine chewable/dispersible tablets were found to be equivalent whether administered as dispersed in water, chewed and swallowed, or swallowed as whole, to the lamotrigine compressed tablets in terms of rate and extent of absorption. In terms of rate and extent of absorption, lamotrigine orally disintegrating tablets whether disintegrated in the mouth or swallowed whole with water were equivalent to the lamotrigine compressed tablets swallowed with water.</p>
<p><span class="Bold Italics">Dose Proportionality</span></p>
<p>In healthy volunteers not receiving any other medications and given single doses, the plasma concentrations of lamotrigine increased in direct proportion to the dose administered over the range of 50 to 400 mg. In 2 small studies (n = 7 and 8) of patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> who were maintained on other AEDs, there also was a linear relationship between dose and lamotrigine plasma concentrations at steady state following doses of 50 to 350 mg twice daily. </p>
<p><span class="Bold Italics">Distribution</span></p>
<p>Estimates of the mean apparent volume of distribution (Vd/F) of lamotrigine following oral administration ranged from 0.9 to 1.3 L/kg. Vd/F is independent of dose and is similar following single and multiple doses in both patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and in healthy volunteers.</p>
<p><span class="Bold Italics">Protein Binding</span></p>
<p>Data from <span class="Italics">in vitro</span> studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials). Because lamotrigine is not highly bound to plasma proteins, clinically significant interactions with other drugs through competition for protein binding sites are unlikely. The binding of lamotrigine to plasma proteins did not change in the presence of therapeutic concentrations of phenytoin, phenobarbital, or valproate. Lamotrigine did not displace other AEDs (carbamazepine, phenytoin, phenobarbital) from protein-binding sites. </p>
<p><span class="Bold Italics">Metabolism</span></p>
<p>Lamotrigine is metabolized predominantly by glucuronic acid conjugation; the major metabolite is an inactive 2-N-glucuronide conjugate. After oral administration of 240 mg of <span class="Sup">14</span>C-lamotrigine (15 mcgCi) to 6 healthy volunteers, 94% was recovered in the urine and 2% was recovered in the feces. The radioactivity in the urine consisted of unchanged lamotrigine (10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), and other unidentified minor metabolites (4%).  </p>
<p><span class="Bold Italics">Enzyme Induction</span></p>
<p>The effects of lamotrigine on the induction of specific families of mixed-function oxidase isozymes have not been systematically evaluated. </p>
<p>Following multiple administrations (150 mg twice daily) to normal volunteers taking no other medications, lamotrigine induced its own metabolism, resulting in a 25% decrease in t<span class="Sub">½</span> and a 37% increase in Cl/F at steady state compared with values obtained in the same volunteers following a single dose. Evidence gathered from other sources suggests that self-induction by lamotrigine may not occur when lamotrigine is given as adjunctive therapy in patients receiving enzyme-inducing drugs such as carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation <span class="Italics">[</span><span class="Italics">see <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a></span><span class="Italics">].</span></p>
<p><span class="Bold Italics">Elimination </span></p>
<p>The elimination half-life and apparent clearance of lamotrigine following oral administration of lamotrigine tablets to adult subjects with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and healthy volunteers is summarized in Table 14. Half-life and apparent oral clearance vary depending on concomitant AEDs.  </p>
<p><span class="Bold Italics">Drug Interactions </span></p>
<p>The apparent clearance of lamotrigine is affected by the coadministration of certain medications <span class="Italics">[</span><span class="Italics">see <a href="#_95924841-207B-D6A0-784D-FDC6FEF07711">Warnings and Precautions (5.8</a>, <a href="#_26778CA4-8AD4-5ECC-F40A-BB45A13D4AA8">5.12)</a>, <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a></span><span class="Italics"> ].</span>  The net effects of drug interactions with lamotrigine are summarized in Tables 13 and 15, followed by details of the drug interaction studies below.   </p>
<table frame="border" rules="all" width="90%">
<caption><span>Table 15. Summary of Drug Interactions With Lamotrigine</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="bottom"><span class="Bold">Drug </span></td>
<td align="center" valign="bottom"><span class="Bold">Drug Plasma Concentration With Adjunctive Lamotrigine<span class="Sup">a</span></span></td>
<td align="center" valign="bottom"><span class="Bold">Lamotrigine Plasma Concentration With Adjunctive Drugs<span class="Sup">b</span></span></td>
</tr>
<tr>
<td align="left" colspan="1">Oral contraceptives<br>(e.g., ethinylestradiol/levonorgestrel)<span class="Sup">c</span>
</td>
<td align="center" colspan="1">↔<span class="Sup">d</span>
</td>
<td align="center" colspan="1">↓</td>
</tr>
<tr>
<td align="left" colspan="1">Aripiprazole</td>
<td align="center" colspan="1">Not assessed</td>
<td align="center" colspan="1">↔<span class="Sup">e</span>
</td>
</tr>
<tr>
<td align="left" colspan="1">Atazanavir/ritonavir</td>
<td align="center" colspan="1">↔<span class="Sup">f</span>
</td>
<td align="center" colspan="1">↓</td>
</tr>
<tr>
<td align="left" colspan="1">Bupropion </td>
<td align="center" colspan="1">Not assessed</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr>
<td align="left" colspan="1">Carbamazepine (CBZ) </td>
<td align="center" colspan="1">↔<span class="Sup">e</span>
</td>
<td align="center" colspan="1">↓</td>
</tr>
<tr>
<td align="left" colspan="1">CBZ epoxide<span class="Sup">f</span>
</td>
<td align="center" colspan="1">?</td>
<td align="center" colspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Felbamate </td>
<td align="center" colspan="1">Not assessed</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr>
<td align="left" colspan="1">Gabapentin </td>
<td align="center" colspan="1">Not assessed</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr>
<td align="left" colspan="1">Levetiracetam </td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr>
<td align="left" colspan="1">Lithium </td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">Not assessed</td>
</tr>
<tr>
<td align="left" colspan="1">Olanzapine </td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">↔<span class="Sup">g</span>
</td>
</tr>
<tr>
<td align="left" colspan="1">Oxcarbazepine </td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr>
<td align="left" colspan="1">10-monohydroxy oxcarbazepine metabolite<span class="Sup">h</span>
</td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Phenobarbital/primidone </td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">↓</td>
</tr>
<tr>
<td align="left" colspan="1">Phenytoin (PHT)</td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">↓</td>
</tr>
<tr>
<td align="left" colspan="1">Pregabalin </td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr>
<td align="left" colspan="1">Rifampin </td>
<td align="center" colspan="1">Not assessed</td>
<td align="center" colspan="1">↓</td>
</tr>
<tr>
<td align="left" colspan="1">Risperidone</td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1">Not assessed</td>
</tr>
<tr>
<td align="left" colspan="1">9-hydroxyrisperidone<span class="Sup">i</span>
</td>
<td align="center" colspan="1">↔</td>
<td align="center" colspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Topiramate</td>
<td align="center" colspan="1">↔<span class="Sup">j</span>
</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr>
<td align="left" colspan="1">Valproate </td>
<td align="center" colspan="1">↓</td>
<td align="center" colspan="1">↑</td>
</tr>
<tr>
<td align="left" colspan="1">Valproate + PHT and/or CBZ </td>
<td align="center" colspan="1">Not assessed</td>
<td align="center" colspan="1">↔</td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Zonisamide </td>
<td align="center" colspan="1">Not assessed</td>
<td align="center" colspan="1">↔</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>From adjunctive clinical trials and volunteer trials. </p>
<p><span class="Sup">b </span>Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteer trials.</p>
<p><span class="Sup">c </span>The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated in clinical trials, although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel combinations.</p>
<p><span class="Sup">d </span>Modest decrease in levonorgestrel.</p>
<p><span class="Sup">e </span>Slight decrease, not expected to be clinically meaningful.</p>
<p><span class="Sup">f</span> Compared to historical controls.</p>
<p><span class="Sup">g </span>Not administered, but an active metabolite of carbamazepine. </p>
<p><span class="Sup">h </span>Not administered, but an active metabolite of oxcarbazepine.</p>
<p><span class="Sup">i</span> Not administered, but an active metabolite of risperidone.</p>
<p><span class="Sup">j </span>Slight increase, not expected to be clinically meaningful.</p>
<p>↔  = No significant effect.</p>
<p>?    = Conflicting data.<span class="Bold"> </span></p>
<p><span class="Bold Italics">Estrogen-Containing Oral Contraceptives</span></p>
<p>In 16 female volunteers, an oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel increased the apparent clearance of lamotrigine (300 mg/day) by approximately 2-fold with mean decreases in AUC of 52% and in C<span class="Sub">max</span> of 39%. In this study, trough serum lamotrigine concentrations gradually increased and were approximately 2-fold higher on average at the end of the week of the inactive hormone preparation compared with trough lamotrigine concentrations at the end of the active hormone cycle. </p>
<p>Gradual transient increases in lamotrigine plasma levels (approximate 2-fold increase) occurred during the week of inactive hormone preparation (pill-free week) for women not also taking a drug that increased the clearance of lamotrigine (carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation) <span class="Italics">[see <a href="#DRUG_INTERACTIONS"> Drug Interactions (7)</a>]</span>. The increase in lamotrigine plasma levels will be greater if the dose of lamotrigine tablets is increased in the few days before or during the pill-free week. Increases in lamotrigine plasma levels could result in dose-dependent adverse reactions. </p>
<p>In the same study, coadministration of lamotrigine (300 mg/day) in 16 female volunteers did not affect the pharmacokinetics of the ethinylestradiol component of the oral contraceptive preparation. There were mean decreases in the AUC and C<span class="Sub">max</span> of the levonorgestrel component of 19% and 12%, respectively. Measurement of serum progesterone indicated that there was no hormonal evidence of ovulation in any of the 16 volunteers, although measurement of serum FSH, LH, and estradiol indicated that there was some loss of suppression of the hypothalamic-pituitary-ovarian axis.  </p>
<p>The effects of doses of lamotrigine other than 300 mg/day have not been systematically evaluated in controlled clinical trials.  </p>
<p>The clinical significance of the observed hormonal changes on ovulatory activity is unknown. However, the possibility of decreased contraceptive efficacy in some patients cannot be excluded. Therefore, patients should be instructed to promptly report changes in their menstrual pattern (e.g., break-through <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>).  </p>
<p>Dosage adjustments may be necessary for women receiving estrogen-containing oral contraceptive preparations <span class="Italics">[see </span><span class="Italics"><a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a></span><span class="Italics">].</span>  </p>
<p><span class="Bold Italics">Other Hormonal Contraceptives or Hormone Replacement Therapy</span></p>
<p> The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the dosage of lamotrigine tablets in the presence of progestogens alone will likely not be needed.</p>
<p><span class="Bold Italics">Aripiprazole</span></p>
<p>In 18 patients with bipolar disorder on a stable regimen of 100 to 400 mg/day of lamotrigine, the lamotrigine AUC and C<span class="Sub">max</span> were reduced by approximately 10% in patients who received aripiprazole 10 to 30 mg/day for 7 days, followed by 30 mg/day for an additional 7 days. This reduction in lamotrigine exposure is not considered clinically meaningful. </p>
<p><span class="Bold Italics">Atazanavir/Ritonavir</span></p>
<p><span class="Bold Italics"></span>In a study in healthy volunteers, daily doses of atazanavir/ritonavir (300 mg/100 mg) reduced the plasma AUC and C<span class="Sub">max</span> of lamotrigine (single 100-mg dose) by an average of 32% and 6%, respectively, and shortened the elimination half­-lives by 27%. In the presence of atazanavir/ritonavir (300 mg/100 mg), the metabolite-to­-lamotrigine ratio was increased from 0.45 to 0.71 consistent with induction of glucuronidation. The pharmacokinetics of atazanavir/ritonavir were similar in the presence of concomitant lamotrigine to the historical data of the pharmacokinetics in the absence of lamotrigine.</p>
<p><span class="Bold Italics">Bupropion</span></p>
<p>The pharmacokinetics of a 100-mg single dose of lamotrigine in healthy volunteers (n = 12) were not changed by coadministration of bupropion sustained-release formulation (150 mg twice daily) starting 11 days before lamotrigine. </p>
<p><span class="Bold Italics">Carbamazepine</span></p>
<p>Lamotrigine tablets have no appreciable effect on steady-state carbamazepine plasma concentration. Limited clinical data suggest there is a higher incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> in patients receiving carbamazepine with lamotrigine than in patients receiving other AEDs with lamotrigine <span class="Italics">[</span><span class="Italics">see </span><span class="Italics"><a href="#_E46D0FC8-F332-5906-7497-1059BE6F286C">Adverse Reactions (6.1)</a></span><span class="Italics"> ]</span>. The mechanism of this interaction is unclear. The effect of lamotrigine on plasma concentrations of carbamazepine-epoxide is unclear. In a small subset of patients (n = 7) studied in a placebo-controlled trial, lamotrigine had no effect on carbamazepine-epoxide plasma concentrations, but in a small, uncontrolled study (n = 9), carbamazepine-epoxide levels increased.  </p>
<p>The addition of carbamazepine decreases lamotrigine steady-state concentrations by approximately 40%.  </p>
<p><span class="Bold Italics">Felbamate</span></p>
<p>In a trial in 21 healthy volunteers, coadministration of felbamate (1,200 mg twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine. <span class="Bold"> </span></p>
<p><span class="Bold Italics">Folate Inhibitors</span></p>
<p>Lamotrigine is a weak inhibitor of dihydrofolate reductase. Prescribers should be aware of this action when prescribing other medications that inhibit folate metabolism. </p>
<p><span class="Bold Italics">Gabapentin</span></p>
<p>Based on a retrospective analysis of plasma levels in 34 subjects who received lamotrigine both with and without gabapentin, gabapentin does not appear to change the apparent clearance of lamotrigine.  </p>
<p><span class="Bold Italics">Levetiracetam</span></p>
<p>Potential drug interactions between levetiracetam and lamotrigine were assessed by evaluating serum concentrations of both agents during placebo-controlled clinical trials. These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine. </p>
<p><span class="Bold Italics">Lithium</span></p>
<p>The pharmacokinetics of lithium were not altered in healthy subjects (n = 20) by coadministration of lamotrigine (100 mg/day) for 6 days.    </p>
<p><span class="Bold Italics"><span class="Bold Italics">Lopinavir/Ritonavir</span></span></p>
<p><span class="Bold Italics"></span>The addition of lopinavir (400 mg twice daily)/ritonavir (100 mg twice daily) decreased the AUC, C<span class="Sub">max</span>, and elimination half-life of lamotrigine by approximately 50% to 55.4% in 18 healthy subjects. The pharmacokinetics of lopinavir/ritonavir were similar with concomitant lamotrigine, compared to that in historical controls.</p>
<p><span class="Bold Italics">Olanzapine</span></p>
<p>The AUC and C<span class="Sub">max </span>of olanzapine were similar following the addition of olanzapine (15 mg once daily) to lamotrigine  (200 mg once daily) in healthy male volunteers (n = 16) compared with the AUC and C<span class="Sub">max</span> in healthy male volunteers receiving olanzapine alone (n = 16).  </p>
<p>In the same trial, the AUC and C<span class="Sub">max</span> of lamotrigine were reduced on average by 24% and 20%, respectively, following the addition of olanzapine to lamotrigine in healthy male volunteers compared with those receiving lamotrigine alone. This reduction in lamotrigine plasma concentrations is not expected to be clinically meaningful.  </p>
<p><span class="Bold Italics">Oxcarbazepine</span></p>
<p>The AUC and C<span class="Sub">max</span> of oxcarbazepine and its active 10-monohydroxy oxcarbazepine metabolite were not significantly different following the addition of oxcarbazepine (600 mg twice daily) to lamotrigine  (200 mg once daily) in healthy male volunteers (n = 13) compared with healthy male volunteers receiving oxcarbazepine alone (n = 13). </p>
<p>In the same trial, the AUC and C<span class="Sub">max</span> of lamotrigine were similar following the addition of oxcarbazepine (600 mg twice daily) to lamotrigine in healthy male volunteers compared with those receiving lamotrigine alone. Limited clinical data suggest a higher incidence of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> with coadministration of lamotrigine and oxcarbazepine compared with lamotrigine alone or oxcarbazepine alone.  </p>
<p><span class="Bold Italics">Phenobarbital, Primidone</span></p>
<p>The addition of phenobarbital or primidone decreases lamotrigine steady-state concentrations by approximately 40%.  </p>
<p><span class="Bold Italics">Phenytoin</span></p>
<p>Lamotrigine has no appreciable effect on steady-state phenytoin plasma concentrations in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. The addition of phenytoin decreases lamotrigine steady-state concentrations by approximately 40%.  </p>
<p><span class="Bold Italics">Pregabalin</span></p>
<p>Steady-state trough plasma concentrations of lamotrigine were not affected by concomitant pregabalin (200 mg 3 times daily) administration. There are no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between lamotrigine and pregabalin.  </p>
<p><span class="Bold Italics">Rifampin</span></p>
<p>In 10 male volunteers, rifampin (600 mg/day for 5 days) significantly increased the apparent clearance of a single 25-mg dose of lamotrigine by approximately 2-fold (AUC decreased by approximately 40%). <span class="Bold"> </span></p>
<p><span class="Bold Italics"></span><span class="Bold Italics">Risperidone</span></p>
<p><span class="Bold Italics"></span>In a 14 healthy volunteers study, multiple oral doses of lamotrigine 400 mg daily had no clinically significant effect on the single-dose pharmacokinetics of risperidone 2 mg and its active metabolite 9-OH risperidone. Following the coadministration of risperidone 2 mg with lamotrigine, 12 of the 14 volunteers reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> compared with 1 out of 20 when risperidone was given alone, and none when lamotrigine was administered alone.</p>
<p><span class="Bold Italics">Topiramate</span></p>
<p>Topiramate resulted in no change in plasma concentrations of lamotrigine. Administration of lamotrigine resulted in a 15% increase in topiramate concentrations.  </p>
<p><span class="Bold Italics">Valproate</span></p>
<p>When lamotrigine was administered to healthy volunteers (n = 18) receiving valproate, the trough steady-state valproate plasma concentrations decreased by an average of 25% over a 3-week period, and then stabilized. However, adding lamotrigine to the existing therapy did not cause a change in valproate plasma concentrations in either adult or pediatric patients in controlled clinical trials.  </p>
<p>The addition of valproate increased lamotrigine steady-state concentrations in normal volunteers by slightly more than 2-fold. In 1 trial, maximal inhibition of lamotrigine clearance was reached at valproate doses between 250 and 500 mg/day and did not increase as the valproate dose was further increased.</p>
<p><span class="Bold Italics">Zonisamide</span></p>
<p>In a study in 18 patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, coadministration of zonisamide (200 to 400 mg/day) with lamotrigine (150 to 500 mg/day for 35 days) had no significant effect on the pharmacokinetics of lamotrigine.  </p>
<p><span class="Bold Italics">Known Inducers or Inhibitors of Glucuronidation</span></p>
<p>Drugs other than those listed above have not been systematically evaluated in combination with lamotrigine. Since lamotrigine is metabolized predominately by glucuronic acid conjugation, drugs that are known to induce or inhibit glucuronidation may affect the apparent clearance of lamotrigine and doses of lamotrigine may require adjustment based on clinical response.  </p>
<p><span class="Bold Italics">Other</span></p>
<p><span class="Italics">In vitro</span> assessment of the inhibitory effect of lamotrigine at OCT2 demonstrate that lamotrigine, but not the N(2)-glucuronide metabolite, is an inhibitor of OCT2 at potentially clinically relevant concentrations, with IC50 value of 53.8 mcM <span class="Italics">[see <a href="#DRUG_INTERACTIONS">Drug Interactions (7)</a>]</span>.</p>
<p>Results of <span class="Italics">in vitro</span> experiments suggest that clearance of lamotrigine is unlikely to be reduced by concomitant administration of amitriptyline, clonazepam, clozapine, fluoxetine, haloperidol, lorazepam, phenelzine, sertraline, or trazodone. Results of <span class="Italics">in vitro</span> experiments suggest that lamotrigine does not reduce the clearance of drugs eliminated predominantly by CYP2D6.  </p>
<p><span class="Bold Italics"><span class="Bold Italics">Specific</span> Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></p>
<p>Twelve volunteers with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> (mean creatinine clearance: 13 mL/min, range: 6 to 23) and another 6 individuals undergoing hemodialysis were each given a single 100-mg dose of lamotrigine. The mean plasma half-lives determined in the study were 42.9 hours (<span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>), 13.0 hours (during hemodialysis), and 57.4 hours (between hemodialysis) compared with 26.2 hours in healthy volunteers. On average, approximately 20% (range: 5.6 to 35.1) of the amount of lamotrigine present in the body was eliminated by hemodialysis during a 4-hour session <span class="Italics">[</span><span class="Italics">see </span><span class="Italics"><a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a></span><span class="Italics">]</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span> </span></p>
<p> The pharmacokinetics of lamotrigine following a single 100-mg dose of lamotrigine were evaluated in 24 subjects with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Classification system) and compared with 12 subjects without <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> were without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (n = 2) or with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (n = 5). The mean apparent clearances of lamotrigine in subjects with mild (n = 12), moderate (n = 5), severe without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (n = 2), and severe with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (n = 5) liver impairment were 0.30 ± 0.09, 0.24 ± 0.1, 0.21 ± 0.04, and 0.15 ± 0.09 mL/min/kg, respectively, as compared with 0.37 ± 0.1 mL/min/kg in the healthy controls. Mean half-lives of lamotrigine in subjects with mild, moderate, severe without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, and severe with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> were 46 ± 20, 72 ± 44, 67 ± 11, and 100 ± 48 hours, respectively, as compared with 33 ± 7 hours in healthy controls <span class="Italics">[</span><span class="Italics">see <span class="Italics"></span><span class="Italics"><a href="#_CB4FB20A-1970-7107-87BD-469701BF64CA">Dosage and Administration (2.1)</a></span></span><span class="Italics">].</span>  </p>
<p><span class="Bold Italics">Age </span></p>
<p><span class="Italics">Pediatric Subjects</span></p>
<p>The pharmacokinetics of lamotrigine  following a single 2 mg/kg dose were evaluated in 2 studies in pediatric subjects (n = 29 for subjects aged 10 months to 5.9 years and n = 26 for subjects aged 5 to 11 years). Forty-three subjects received concomitant therapy with other AEDs and 12 subjects received lamotrigine  as monotherapy. Lamotrigine pharmacokinetic parameters for pediatric patients are summarized in Table 16.  </p>
<p>Population pharmacokinetic analyses involving subjects aged 2 to 18 years demonstrated that lamotrigine clearance was influenced predominantly by total body weight and concurrent AED therapy. The oral clearance of lamotrigine was higher, on a body weight basis, in pediatric patients than in adults. Weight-normalized lamotrigine clearance was higher in those subjects weighing less than 30 kg compared with those weighing greater than 30 kg. Accordingly, patients weighing less than 30 kg may need an increase of as much as 50% in maintenance doses, based on clinical response, as compared with subjects weighing more than 30 kg being administered the same AEDs <span class="Italics">[</span><span class="Italics">see Dosage and Administration (2.2)</span><span class="Italics">]</span>. These analyses also revealed that, after accounting for body weight, lamotrigine clearance was not significantly influenced by age. Thus, the same weight-adjusted doses should be administered to children irrespective of differences in age. Concomitant AEDs which influence lamotrigine clearance in adults were found to have similar effects in children.</p>
<table frame="border" rules="all" width="90%">
<caption><span>Table 16. Mean Pharmacokinetic Parameters in Pediatric Subjects With <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="10%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="bottom">Pediatric Study Population</td>
<td align="center" valign="bottom">Number of Subjects</td>
<td align="center" valign="bottom">T<span class="Sub">max</span>(h)</td>
<td align="center" valign="bottom">t<span class="Sub">½</span>(h)</td>
<td align="center" valign="bottom">Cl/F(mL/min/kg)</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Ages 10 months-5.3 years </span></td></tr>
<tr>
<td align="left" colspan="1" rowspan="2">Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<span class="Sup">a</span>
</td>
<td align="center" colspan="1">10</td>
<td align="center" colspan="1">3.0</td>
<td align="center" colspan="1">7.7</td>
<td align="center" colspan="1">3.62</td>
</tr>
<tr valign="top">
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(10.0-5.9)</td>
<td align="center" colspan="1">(5.7-11.4)</td>
<td align="center" colspan="1">(2.44-5.28)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Subjects taking AEDs with no known effect on the apparent clearance of lamotrigine</td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">5.2</td>
<td align="center" colspan="1">19.0</td>
<td align="center" colspan="1">1.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1">(2.9-6.1)</td>
<td align="center" colspan="1">(12.9-27.1)</td>
<td align="center" colspan="1">(0.75-2.42)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Subjects taking valproate only </td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1">2.9</td>
<td align="center" colspan="1">44.9</td>
<td align="center" colspan="1">0.47</td>
</tr>
<tr>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(1.0-6.0)</td>
<td align="center" colspan="1">(29.5-52.5)</td>
<td align="center" colspan="1">(0.23-0.77)</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Ages 5-11 years </span></td></tr>
<tr>
<td align="left" colspan="1" rowspan="2">Subjects taking carbamazepine, phenytoin, phenobarbital, or Subjects taking carbamazepine, primidone<span class="Sup">a</span>
</td>
<td align="center" colspan="1">7</td>
<td align="center" colspan="1">1.6</td>
<td align="center" colspan="1">7.0</td>
<td align="center" colspan="1">2.54</td>
</tr>
<tr>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(1.0-3.0)</td>
<td align="center" colspan="1">(3.8-9.8)</td>
<td align="center" colspan="1">(1.35-5.58)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Subjects taking carbamazepine, phenytoin, phenobarbital, or Subjects taking carbamazepine, primidone<span class="Sup">a</span> plus valproate </td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1">3.3</td>
<td align="center" colspan="1">19.1</td>
<td align="center" colspan="1">0.89</td>
</tr>
<tr>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(1.0-6.4)</td>
<td align="center" colspan="1">(7.0-31.2)</td>
<td align="center" colspan="1">(0.39-1.93)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">
<span class="Sup"></span>Subjects taking valproate only<span class="Sup">b</span>
</td>
<td align="center" colspan="1">3</td>
<td align="center" colspan="1">4.5</td>
<td align="center" colspan="1">65.8</td>
<td align="center" colspan="1">.024</td>
</tr>
<tr>
<td align="center" colspan="1"></td>
<td align="center" colspan="1">(3.0-6.0)</td>
<td align="center" colspan="1">(50.7-73.7)</td>
<td align="center" colspan="1">(0.21-0.26)</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Ages 13-18 years</span></td></tr>
<tr>
<td align="left" colspan="1">Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<span class="Sup">a</span>
</td>
<td align="center" colspan="1">11</td>
<td align="center" colspan="1"><span class="Sup">c</span></td>
<td align="center" colspan="1"><span class="Sup">c</span></td>
<td align="center" colspan="1">1.3</td>
</tr>
<tr>
<td align="left" colspan="1">Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<span class="Sup">a</span> plus valproate </td>
<td align="center" colspan="1">8</td>
<td align="center" colspan="1"><span class="Sup">c</span></td>
<td align="center" colspan="1"><span class="Sup">c</span></td>
<td align="center" colspan="1">0.5</td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Subjects taking valproate only </td>
<td align="center" colspan="1">4</td>
<td align="center" colspan="1"><span class="Sup">c</span></td>
<td align="center" colspan="1"><span class="Sup">c</span></td>
<td align="center" colspan="1">0.3</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Carbamazepine, phenytoin, phenobarbital, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir have also been shown to increase the apparent clearance of lamotrigine <span class="Italics">[see <a href="#DRUG_INTERACTIONS"> Drug Interactions (7)</a>]</span>. </p>
<p><span class="Sup">b</span> Two subjects were included in the calculation for mean T<span class="Sub">max</span>.</p>
<p><span class="Sup">c</span> Parameter not estimated.<span class="Sup"></span></p>
<p><span class="Bold Italics">Elderly </span></p>
<p>The pharmacokinetics of lamotrigine following a single 150-mg dose of lamotrigine were evaluated in 12 elderly volunteers between the ages of 65 and 76 years (mean creatinine clearance = 61 mL/min, range: 33 to 108 mL/min). The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg). <span class="Bold"> </span></p>
<p><span class="Bold Italics">Gender </span></p>
<p>The clearance of lamotrigine is not affected by gender. However, during dose escalation of lamotrigine in 1 clinical trial in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> on a stable dose of valproate (n = 77), mean trough lamotrigine concentrations unadjusted for weight were 24% to 45% higher (0.3 to 1.7 mcg/mL) in females than in males. <span class="Bold"> </span></p>
<p><span class="Bold Italics">Race </span></p>
<p>The apparent oral clearance of lamotrigine was 25% lower in non-Caucasians than Caucasians. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="NONCLINICAL_TOXICOLOGY"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY"></a><a name="section-12.1"></a><p></p>
<h2> 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First">No evidence of carcinogenicity was seen in mouse or rat following oral administration of lamotrigine for up to 2 years at doses up to 30 mg/kg/day and 10 to 15 mg/kg/day in mouse and rat, respectively. The highest doses tested are less than the human dose of 400 mg/day on a body surface area (mg/m<span class="Sup">2</span>) basis.</p>
<p>Lamotrigine was negative in <span class="Italics">in vitro</span> gene mutation (Ames and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> tk) assays and in clastogenicity (<span class="Italics">in vitro</span> human lymphocyte and <span class="Italics">in vivo</span> rat bone marrow) assays.</p>
<p>No evidence of impaired fertility was detected in rats given oral doses of lamotrigine up to 20 mg/kg/day . The highest dose tested is less than the human dose of 400 mg/day on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CLINICAL_STUDIES"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34092-7">
<a name="_2E5045E5-99AC-16DD-CD30-2944AB38CF14"></a><a name="section-13.1"></a><p></p>
<h2><span class="None">14.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> </span></h2>
<p class="First"><span class="Bold Italics">Monotherapy with Lamotrigine Tablets in Adults with Partial<span class="Bold Italics">-Onset</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> Already Receiving Treatment with Carbamazepine, Phenytoin, Phenobarbital, or Primidone as the Single Antiepileptic Drug</span></p>
<p>The effectiveness of monotherapy with lamotrigine tablets was established in a multicenter, double-blind clinical trial enrolling 156 adult outpatients with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. The patients experienced at least 4 simple partial-onset, complex partial-onset, and/or secondarily generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during each of 2 consecutive 4-week periods while receiving carbamazepine or phenytoin monotherapy during baseline. Lamotrigine tablets (target dose of 500 mg/day) or valproate (1,000 mg/day) was added to either carbamazepine or phenytoin monotherapy over a 4-week period. Patients were then converted to monotherapy with lamotrigine tablets or valproate during the next 4 weeks, then continued on monotherapy for an additional 12-week period.</p>
<p>Trial endpoints were completion of all weeks of trial treatment or meeting an escape criterion. Criteria for escape relative to baseline were: (1) doubling of average monthly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> count, (2) doubling of highest consecutive 2-day <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency, (3) emergence of a new <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> type (defined as a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> that did not occur during the 8-week baseline) that is more severe than <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types that occur during study treatment, or (4) clinically significant prolongation of generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>. The primary efficacy variable was the proportion of patients in each treatment group who met escape criteria. </p>
<p>The percentages of patients who met escape criteria were 42% (32/76) in the group receiving lamotrigine tablets and 69% (55/80) in the valproate group. The difference in the percentage of patients meeting escape criteria was statistically significant (P = 0.0012) in favor of lamotrigine tablets. No differences in efficacy based on age, sex, or race were detected. </p>
<p>Patients in the control group were intentionally treated with a relatively low dose of valproate; as such, the sole objective of this trial was to demonstrate the effectiveness and safety of monotherapy with lamotrigine tablets and cannot be interpreted to imply the superiority of lamotrigine tablets to an adequate dose of valproate. </p>
<p><span class="Bold Italics">Adjunctive Therapy with Lamotrigine Tablets in Adults with Partial<span class="Bold Italics">-Onset</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>The effectiveness of lamotrigine tablets as adjunctive therapy (added to other AEDs) was initially established in 3 pivotal, multicenter, placebo-controlled, double-blind clinical trials in 355 adults with refractory partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. The patients had a history of at least 4 partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per month in spite of receiving 1 or more AEDs at therapeutic concentrations and in 2 of the trials were observed on their established AED regimen during baselines that varied between 8 to 12 weeks. In the third trial, patients were not observed in a prospective baseline. In patients continuing to have at least 4 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per month during the baseline, lamotrigine tablets or placebo was then added to the existing therapy. In all 3 trials, change from baseline in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency was the primary measure of effectiveness. The results given below are for all partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in the intent-to-treat population (all patients who received at least 1 dose of treatment) in each trial, unless otherwise indicated. The median <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency at baseline was 3 per week while the mean at baseline was 6.6 per week for all patients enrolled in efficacy trials.  </p>
<p>One trial (n = 216) was a double-blind, placebo-controlled, parallel trial consisting of a 24-week treatment period. Patients could not be on more than 2 other anticonvulsants and valproate was not allowed. Patients were randomized to receive placebo, a target dose of 300 mg/day of lamotrigine tablets, or a target dose of 500 mg/day of lamotrigine tablets. The median reductions in the frequency of all partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> relative to baseline were 8% in patients receiving placebo, 20% in patients receiving 300-mg/day of lamotrigine tablets, and 36% in patients receiving 500 mg/day of lamotrigine tablets. The <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency reduction was statistically significant in the 500 mg/day group compared with the placebo group, but not in the 300 mg/day group.  </p>
<p>A second trial (n = 98) was a double-blind, placebo-controlled, randomized, crossover trial consisting of two 14-week treatment periods (the last 2 weeks of which consisted of dose tapering) separated by a 4-week washout period. Patients could not be on more than 2 other anticonvulsants and valproate was not allowed. The target dose of lamotrigine tablets was 400 mg/day. When the first 12 weeks of the treatment periods were analyzed, the median change in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency was a 25% reduction on lamotrigine tablets  compared with placebo (P&lt;0.001).  </p>
<p>The third trial (n = 41) was a double-blind, placebo-controlled, crossover trial consisting of two 12-week treatment periods separated by a 4-week washout period. Patients could not be on more than 2 other anticonvulsants. Thirteen patients were on concomitant valproate; these patients received 150 mg/day of lamotrigine tablets. The 28 other patients had a target dose of 300 mg/day of lamotrigine tablets. The median change in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency was a 26% reduction on lamotrigine tablets compared with placebo (P&lt;0.01).  </p>
<p>No differences in efficacy based on age, sex, or race, as measured by change in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency, were detected.  </p>
<p><span class="Bold Italics">Adjunctive Therapy with Lamotrigine Tablets in Pediatric Patients with Partial<span class="Bold Italics">-Onset </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>The effectiveness of lamotrigine as adjunctive therapy in pediatric patients with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was established in a multicenter, double-blind, placebo-controlled trial in 199 patients aged 2 to 16 years (n = 98 on lamotrigine tablets, n = 101 on placebo). Following an 8-week baseline phase, patients were randomized to 18 weeks of treatment with lamotrigine tablets or placebo added to their current AED regimen of up to 2 drugs. Patients were dosed based on body weight and valproate use. Target doses were designed to approximate 5 mg/kg/day for patients taking valproate (maximum dose: 250 mg/day) and 15 mg/kg/day for the patients not taking valproate (maximum dose: 750 mg/day). The primary efficacy endpoint was percentage change from baseline in all partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. For the intent-to-treat population, the median reduction of all partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was 36% in patients treated with lamotrigine tablets and 7% on placebo, a difference that was statistically significant (P&lt;0.01).  </p>
<p><span class="Bold Italics">Adjunctive Therapy with Lamotrigine Tablets in Pediatric and Adult Patients with Lennox-Gastaut Syndrome</span></p>
<p>The effectiveness of lamotrigine tablets as adjunctive therapy in patients with Lennox-Gastaut syndrome was established in a multicenter, double-blind, placebo-controlled trial in 169 patients aged 3 to 25 years (n = 79 on lamotrigine tablets, n = 90 on placebo). Following a 4-week single-blind, placebo phase, patients were randomized to 16 weeks of treatment with lamotrigine tablets or placebo added to their current AED regimen of up to 3 drugs. Patients were dosed on a fixed-dose regimen based on body weight and valproate use. Target doses were designed to approximate 5 mg/kg/day for patients taking valproate (maximum dose: 200 mg/day) and 15 mg/kg/day for patients not taking valproate (maximum dose: 400 mg/day). The primary efficacy endpoint was percentage change from baseline in major motor <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (atonic, tonic, major myoclonic, and tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>). For the intent-to-treat population, the median reduction of major motor <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was 32% in patients treated with lamotrigine tablets and 9% on placebo, a difference that was statistically significant (P&lt;0.05). Drop attacks were significantly reduced by lamotrigine tablets (34%) compared with placebo (9%), as were tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> (36% reduction versus 10% increase for lamotrigine tablets and placebo, respectively).  </p>
<p><span class="Bold Italics">Adjunctive Therapy with Lamotrigine Tablets in Pediatric and Adult Patients with Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span></span></p>
<p> The effectiveness of lamotrigine tablets as adjunctive therapy in patients with PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was established in a multicenter, double-blind, placebo-controlled trial in 117 pediatric and adult patients aged 2 years and older (n = 58 on lamotrigine tablets, n = 59 on placebo). Patients with at least 3 PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during an 8-week baseline phase were randomized to 19 to 24 weeks of treatment with lamotrigine tablets or placebo added to their current AED regimen of up to 2 drugs. Patients were dosed on a fixed-dose regimen, with target doses ranging from 3 to 12 mg/kg/day for pediatric patients and from 200 to 400 mg/day for adult patients based on concomitant AEDs. </p>
<p>The primary efficacy endpoint was percentage change from baseline in PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. For the intent-to-treat population, the median percent reduction in PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was 66% in patients treated with lamotrigine tablets and 34% on placebo, a difference that was statistically significant (<span class="Italics">P</span> = 0.006).</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="_2A78EA81-3F2C-BD5F-283E-344F18D700A5"></a><a name="section-13.2"></a><p></p>
<h2><span class="None">14.2  Bipolar Disorder </span></h2>
<p class="First">The effectiveness of lamotrigine in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> was established in 2 multicenter, double-blind, placebo-controlled trials in adult patients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. Trial 1 enrolled patients with a current or recent (within 60 days) <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> as defined by DSM-IV and Trial 2 included patients with a current or recent (within 60 days) episode of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> as defined by DSM-IV. Both trials included a cohort of patients (30% of 404 subjects in Trial 1 and 28% of 171 patients in Trial 2) with rapid cycling bipolar disorder (4 to 6 episodes per year).  </p>
<p>In both trials, patients were titrated to a target dose of 200 mg of lamotrigine tablets, as add-on therapy or as monotherapy with gradual withdrawal of any psychotropic medications during an 8- to 16-week open-label period. Overall 81% of 1,305 patients participating in the open-label period were receiving 1 or more other psychotropic medications, including benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics (including olanzapine), valproate, or lithium, during titration of lamotrigine tablets. Patients with a CGI-severity score of 3 or less maintained for at least 4 continuous weeks, including at least the final week on monotherapy with lamotrigine tablets, were randomized to a placebo-controlled, double-blind treatment period for up to 18 months. The primary endpoint was TIME (time to intervention for a mood episode or one that was emerging, time to discontinuation for either an adverse event that was judged to be related to bipolar disorder, or for lack of efficacy). The mood episode could be <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, or a mixed episode.  </p>
<p>In Trial 1, patients received double-blind monotherapy with lamotrigine tablets, 50 mg/day (n = 50), lamotrigine tablets 200 mg/day (n = 124), lamotrigine tablets 400 mg/day (n = 47), or placebo (n = 121). Lamotrigine tablets (200- and 400-mg/day treatment groups combined) were superior to placebo in delaying the time to occurrence of a mood episode. Separate analyses of the 200 and 400 mg/day dose groups revealed no added benefit from the higher dose.  </p>
<p>In Trial 2, patients received double-blind monotherapy with lamotrigine tablets (100 to 400 mg/day, n = 59), or placebo (n = 70). Lamotrigine tablets were superior to placebo in delaying time to occurrence of a mood episode. The mean dose of lamotrigine tablets was about 211 mg/day.  </p>
<p>Although these trials were not designed to separately evaluate time to the occurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, a combined analysis for the 2 trials revealed a statistically significant benefit for lamotrigine over placebo in delaying the time to occurrence of both <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, although the finding was more robust for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HOW_SUPPLIED"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">Lamotrigine Tablets, USP 25 mg </span></p>
<p> Lamotrigine tablets 25 mg are available for oral administration as white to off-white, round, flat-faced bevelled-edge tablets, engraved “LAM? over score “25? on one side, “APO? on the other side. </p>
<p>Bottles of 30 (NDC 60505-2663-3)</p>
<p>Bottles of 100 (NDC 60505-2663-1)</p>
<p>Bottles of 500 (NDC 60505-2663-5)</p>
<p>Bottles of 1,000 (NDC 60505-2663-8)</p>
<p><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> of 100 (NDC 60505-2663-0) <span class="Bold"></span></p>
<p><span class="Bold">Lamotrigine Tablets, USP 100 mg</span></p>
<p> Lamotrigine tablets 100 mg are available for oral administration as peach, round, flat faced bevelled-edge tablets, engraved “LAM? over score “100? on one side, “APO? on the other side. </p>
<p>Bottles of 30 (NDC 60505-2664-3)</p>
<p>Bottles of 100 (NDC 60505-2664-1)</p>
<p>Bottles of 500 (NDC 60505-2664-5)</p>
<p>Bottles of 1,000 (NDC 60505-2664-8)</p>
<p><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> of 100 (NDC 60505-2664-0) </p>
<p><span class="Bold">Lamotrigine Tablets, USP 150 mg</span></p>
<p> Lamotrigine tablets 150 mg are available for oral administration as cream, round, flat faced bevelled-edge tablets, engraved “LAM? over score “150? on one side, “APO? on the other side.<span class="Bold"> </span></p>
<p> Bottles of 30 (NDC 60505-2665-3)</p>
<p>Bottles of 60 (NDC 60505-2665-6)</p>
<p>Bottles of 100 (NDC 60505-2665-1)</p>
<p>Bottles of 500 (NDC 60505-2665-5)</p>
<p>Bottles of 1,000 (NDC 60505-2665-8)</p>
<p><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> of 100 (NDC 60505-2665-0) </p>
<p><span class="Bold">Lamotrigine Tablets, USP 200 mg</span></p>
<p> Lamotrigine tablets 200 mg are available for oral administration as blue, round, flat faced bevelled-edge tablets, engraved “LAM? over score “200? on one side, “APO? on the other side. </p>
<p>Bottles of 30 (NDC 60505-2680-3)</p>
<p>Bottles of 60 (NDC 60505-2680-6)</p>
<p>Bottles of 500 (NDC 60505-2680-5)</p>
<p>Bottles of 1,000 (NDC 60505-2680-8)</p>
<p><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> of 100 (NDC 60505-2680-0) </p>
<p><span class="Bold">Storage <br></span><span class="Bold">Store at 20º to 25ºC (68º to 77ºF); excursions permitted from 15º to 30ºC (59º to 86ºF) [see USP Controlled Room Temperature].</span> </p>
<p>Dispense in a tight, light-resistant container [see USP].</p>
<p><span class="Italics">Blisterpacks:</span> If the product is dispensed in a blisterpack, the patient should be advised to examine the blisterpack before use and not use if <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> are torn, broken, or missing. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INFORMATION_FOR_PATIENTS"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></p>
<p>Prior to initiation of treatment with lamotrigine tablets, inform patients that a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>) may herald a serious medical event and instruct them to report any such occurrence to their physician immediately.</p>
<p><span class="Bold">Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span>, and Organ Failure</span></p>
<p>Inform patients that multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and acute <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiorgan failure</span> may occur with lamotrigine. Isolated organ failure or isolated <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> without evidence of multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> may also occur. Instruct patients to contact their physician immediately if they experience any signs or symptoms of these conditions <span class="Italics">[</span><span class="Italics">see <a href="#_7D99A3CE-2D69-6428-4F47-35B3A62230D0">Warnings and Precautions (5.2</a>, <a href="#_041AE776-AB46-DF3B-06A8-1EA3EC330FCF">5.3</a>)</span><span class="Italics">].</span></p>
<p><span class="Bold">Suicidal Thinking and Behavior</span></p>
<p>Inform patients, their caregivers, and families that AEDs, including lamotrigine tablets, may increase the risk of suicidal thoughts and behavior. Instruct them to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior or thoughts about self-harm. Instruct them to immediately report behaviors of concern to their physician.</p>
<p><span class="Bold">Worsening of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>Advise patients to notify their physician if worsening of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control occurs.</p>
<p><span class="Bold">Central Nervous System Adverse Effects</span></p>
<p>Inform patients that lamotrigine tablets may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and other symptoms and signs of central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Accordingly, instruct them neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on lamotrigine tablets to gauge whether or not it adversely affects their mental and/or motor performance.</p>
<p><span class="Bold">Pregnancy and Nursing</span></p>
<p>Instruct patients to notify their physician if they become pregnant or intend to become pregnant during therapy and if they intend to breastfeed or are breastfeeding an infant.</p>
<p>Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 <span class="Italics">[</span><span class="Italics">see </span><span class="Italics"><a href="#PREGNANCY">Use in Specific Populations (8.1)</a></span><span class="Italics">].</span></p>
<p>Inform patients who intend to breastfeed that lamotrigine is present in breast milk and advise them to monitor their child for potential adverse effects of this drug. Discuss the benefits and risks of continuing breastfeeding.</p>
<p><span class="Bold">Oral Contraceptive Use</span></p>
<p>Instruct women to notify their physician if they plan to start or stop use of oral contraceptives or other female hormonal preparations. Starting estrogen-containing oral contraceptives may significantly decrease lamotrigine plasma levels and stopping estrogen-containing oral contraceptives (including the pill-free week) may significantly increase lamotrigine plasma levels <span class="Italics">[see <a href="#_95924841-207B-D6A0-784D-FDC6FEF07711">Warnings and Precautions (5.8)</a>, <a href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</a>].</span> Also instruct women to promptly notify their physician if they experience adverse reactions or changes in menstrual pattern (e.g., break-through <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) while receiving lamotrigine tablets in combination with these medications.</p>
<p><span class="Bold">Discontinuing Lamotrigine Tablets, USP</span></p>
<p>Instruct patients to notify their physician if they stop taking lamotrigine tablets for any reason and not to resume lamotrigine tablets without consulting their physician.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span></span></p>
<p>Inform patients that lamotrigine may cause <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>. Instruct them to notify their physician immediately if they develop signs and symptoms of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiff neck</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, abnormal sensitivity to light, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> while taking lamotrigine.</p>
<p><span class="Bold">Potential Medication Errors</span></p>
<p>To avoid a medication error of using the wrong drug or formulation, strongly advise patients to visually inspect their tablets to verify that they are lamotrigine, as well as the correct formulation of, lamotrigine tablets each time they fill their prescription<span class="None"> </span><span class="Italics">[see Dosage Forms and Strengths (<a href="#_F879CBD7-7A02-1A5E-1438-FDF8F7372F0F">3.1</a>), How Supplied/Storage and Handling (<a href="#HOW_SUPPLIED">16</a>)]</span>. Refer the patient to the Medication Guide that provides depictions of the lamotrigine tablets.</p>
<p><span class="Bold">APOTEX INC.</span></p>
<p><span class="Bold">LAMOTRIGINE TABLETS, USP</span></p>
<p><span class="Bold">25 mg, 100 mg, 150 mg and 200 mg</span></p>
<table><tbody class="Headless">
<tr class="First">
<td>
<p class="First"></p>
<span class="Bold">Manufactured by</span>
</td>
<td>
<p class="First"></p>
<span class="Bold">Manufactured for</span>
</td>
</tr>
<tr>
<td><p class="First">Apotex Inc.</p></td>
<td><p class="First">Apotex Corp.</p></td>
</tr>
<tr>
<td>Toronto, Ontario</td>
<td>Weston, Florida</td>
</tr>
<tr class="Last">
<td>Canada M9L 1T9</td>
<td>33326, USA</td>
</tr>
</tbody></table>
<p>April 2015</p>
<p>Rev. 8 </p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="_ECB4D4E2-7D9B-BE53-B31F-27F1C16F1F80"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">MEDICATION GUIDE</span></h1>
<p class="First"><span class="Bold">Lamotrigine Tablets, USP</span></p>
<p> (la moe' tri jeen) <span class="Bold"></span><span class="Bold Insert"></span></p>
<p>Read this Medication Guide before you start taking lamotrigine tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about lamotrigine tablets, ask your healthcare provider or pharmacist. </p>
<p><span class="Bold">What is the most important information I should know about lamotrigine tablets?</span>  </p>
<p><span class="Bold">1. <span class="Bold">Lamotrigine tablets may cause a serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> that may cause you to be hospitalized or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></span></p>
<p>There is no way to tell if a mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> will become more serious. A serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> can happen at any time during your treatment with lamotrigine tablets, but is more likely to happen within the first 2 to 8 weeks of treatment. Children aged between 2 and 16 years have a higher chance of getting this serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> while taking lamotrigine tablets.  </p>
<p>The risk of getting a serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> is higher if you:    </p>
<ul>
<li>take lamotrigine tablets while taking valproate [DEPAKENE<span class="Sup">®</span> (valproic acid) or DEPAKOTE<span class="Sup">®</span> (divalproex sodium)].</li>
<li> take a higher starting dose of lamotrigine tablets than your healthcare provider prescribed.</li>
<li> increase your dose of lamotrigine tablets faster than prescribed.   </li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you have any of the following:  </span></p>
<ul>
<li><span class="Bold">a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> </span></li>
<li>
<span class="Bold"></span> <span class="Bold"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin </span>
</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> </span></li>
<li><span class="Bold">painful sores in your mouth or around your eyes </span></li>
</ul>
<p>These symptoms may be the first signs of a serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>. A healthcare provider should examine you to decide if you should continue taking lamotrigine tablets. </p>
<p><span class="Bold">2.</span><span class="None"></span> Other serious reactions, including serious blood problems or liver problems. Lamotrigine can also cause other types of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> or serious problems that may affect organs and other parts of your body like your liver or blood cells. You may or may not have a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with these types of reactions. Call your healthcare provider right away if you have any of these symptoms:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>frequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, or tongue</li>
<li>swollen lymph glands</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></li>
<li>yellowing of your skin or the white part of your eyes</li>
</ul>
<p><span class="Bold">3. Like other antiepileptic drugs, lamotrigine tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. </span> </p>
<p><span class="Bold">Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:  </span></p>
<ul>
<li> thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying </li>
<li> attempt to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> </li>
<li> new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </li>
<li> new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </li>
<li> feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> </li>
<li> trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) </li>
<li> new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> </li>
<li> acting aggressive, being angry, or violent </li>
<li> acting on dangerous impulses </li>
<li> an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li> other unusual changes in behavior or mood  </li>
</ul>
<p><span class="Bold">Do not stop lamotrigine tablets without first talking to a healthcare provider. </span></p>
<ul>
<li> Stopping lamotrigine tablets suddenly can cause serious problems. </li>
<li> Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.  </li>
</ul>
<p><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions? </span></p>
<ul>
<li> Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. </li>
<li> Keep all follow-up visits with your healthcare provider as scheduled. </li>
<li> Call your healthcare provider between visits as needed, especially if you are worried about symptoms.  </li>
</ul>
<p><span class="Bold">4. Lamotrigine </span>may rarely cause <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, a serious <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the protective membrane that covers the brain and spinal cord. </p>
<p>Call your healthcare provider right away if you have any of the following symptoms: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiff neck</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>unusual sensitivity to light </li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span></li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> </li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> has many causes other than lamotrigine, which your doctor would check for if you developed <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> while taking lamotrigine. </p>
<p><span class="Bold">Lamotrigine tablets can have other serious side effects</span>. </p>
<p>For more information ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you. Be sure to read the section below entitled “What are the possible side effects of lamotrigine tablets?? </p>
<p><span class="Bold">5. Patients prescribed lamotrigine tablets have sometimes been given the wrong medicine because many medicines have names similar to lamotrigine tablets so always check that you receive lamotrigine tablets. </span>              </p>
<p>Taking the wrong medication can cause serious health problems. When your healthcare provider gives you a prescription for lamotrigine tablets </p>
<ul>
<li>Make sure you can read it clearly. </li>
<li> Talk to your pharmacist to check that you are given the correct medicine.</li>
<li> Each time you fill your prescription, check the tablets you receive against the pictures of the tablets below.</li>
</ul>
<p>These pictures show the distinct wording, colors, and shapes of the tablets that help to identify the right strength of lamotrigine tablets. Immediately call your pharmacist if you receive a lamotrigine tablet that does not look like one of the tablets shown below, as you may have received the wrong medication. </p>
<p><span class="Bold">Lamotrigine Tablets, USP</span></p>
<table frame="border" rules="all" width="100%"><tbody class="Headless">
<tr class="First">
<td>25 mg, white to off-white, engraved “LAM│25? on one side, “APO? on the other</td>
<td rowspan="1"><img alt="25mg-tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=25mg-tablet.jpg"></td>
</tr>
<tr>
<td colspan="1">100 mg, peach, engraved “LAM<span class="Bold">│</span>100? on one side, “APO? on the other</td>
<td colspan="1"><img alt="100mg-tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=100mg-tablet.jpg"></td>
</tr>
<tr>
<td colspan="1">150 mg, cream, engraved “LAM<span class="Bold">│</span>150? on one side, “APO? on the other</td>
<td colspan="1"><img alt="150mg-tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=150mg-tablet.jpg"></td>
</tr>
<tr class="Last">
<td colspan="1">200 mg, blue, engraved “LAM<span class="Bold">│</span>200? on one side, “APO? on the other</td>
<td colspan="1"><img alt="200mg-tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=200mg-tablet.jpg"></td>
</tr>
</tbody></table>
<p><span class="Bold">What are lamotrigine tablets, USP? </span>  </p>
<p>Lamotrigine tablets are a prescription medicine used: </p>
<ol>
<li> together with other medicines to treat certain types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> of Lennox-Gastaut syndrome) in people aged 2 years and older.  </li>
<li> alone when changing from 1 other medicine used to treat partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in people aged 16 years and older.  </li>
<li>for the long-term treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> to lengthen the time between mood episodes in people aged 18 years and older who have been treated for mood episodes with other medicine.  </li>
</ol>
<p>It is not known if lamotrigine tablets are safe or effective in children or teenagers younger than 18 years with mood disorders such as bipolar disorder or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
<p>It is not known if lamotrigine tablets are safe or effective when used alone as the first treatment of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="Bold">Who should not take lamotrigine tablets, USP? </span></p>
<p>You should not take lamotrigine tablets if you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to lamotrigine or to any of the inactive ingredients in lamotrigine tablets. See the end of this leaflet for a complete list of ingredients in lamotrigine tablets. </p>
<p><span class="Bold">What should I tell my healthcare provider before taking lamotrigine tablets, USP? </span></p>
<p> Before taking lamotrigine tablets tell your healthcare provider about all of your medical conditions, including if you: </p>
<ul>
<li> have had a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to another antiseizure medicine.   </li>
<li> have or have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood problems, or suicidal thoughts or behavior.</li>
<li>have had <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> after taking lamotrigine tablets  </li>
<li>are taking oral contraceptives (birth control pills) or other female hormonal medicines. Do not start or stop taking birth control pills or other female hormonal medicine until you have talked with your healthcare provider. Tell your healthcare provider if you have any changes in your menstrual pattern such as breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Stopping these medicines may cause side effects (such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">lack of coordination</span>, or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>). Starting these medicines may lessen how well lamotrigine tablets works. </li>
<li>are pregnant or plan to become pregnant. It is not known if lamotrigine tablets will harm your unborn baby. If you become pregnant while taking lamotrigine tablets talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry.  You can enroll in this registry by calling 1-888-233-2334.  The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.  </li>
<li>are breastfeeding. Lamotrigine passes into breast milk and may cause side effects in a breastfed baby. If you breastfeed while taking lamotrigine, watch your baby closely for trouble breathing, episodes of temporarily stopping breathing, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, or poor sucking. Call your baby’s healthcare provider right away if you see any of these problems. Talk to your healthcare provider about the best way to feed your baby if you take lamotrigine.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take or if you are planning to take a new medicine, including prescription and non-prescription medicines, vitamins, and herbal supplements. If you use lamotrigine tablets with certain other medicines, they can affect each other, causing side effects.  </p>
<p><span class="Bold">How should I take lamotrigine tablets, USP? <br></span> Take lamotrigine tablets exactly as prescribed.  </p>
<ul>
<li> Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.  </li>
<li>Do not stop taking lamotrigine tablets without talking to your healthcare provider. Stopping lamotrigine tablets suddenly may cause serious problems.  For example, if you have <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and you stop taking lamotrigine tablets suddenly, you may have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that do not stop. Talk with your healthcare provider about how to stop lamotrigine tablets slowly.  </li>
<li>If you miss a dose of lamotrigine tablets take it as soon as you remember.  If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. <span class="Bold">Do not take 2 doses at the same time. </span>
</li>
<li>If you take too much lamotrigine, call your healthcare provider or your local Poison Control Center or go to the nearest hospital emergency room right away.</li>
<li> You may not feel the full effect of lamotrigine tablets for several weeks  </li>
<li> If you have <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, tell your healthcare provider if your <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> get worse or if you have any new types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.  </li>
<li> Swallow lamotrigine tablets whole.  </li>
<li> If you have trouble swallowing lamotrigine tablets, tell your healthcare provider because there may be another form of lamotrigine you can take.  </li>
<li>If you receive lamotrigine tablets in a blisterpack, examine the blisterpack before use.  Do not use if <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> are torn, broken, or missing.  </li>
</ul>
<p><span class="Bold">What should I avoid while taking lamotrigine tablets, USP? </span></p>
<ul><li> Do not drive a car or operate complex, hazardous machinery until you know how lamotrigine tablets affect you. <span class="Bold"> </span>
</li></ul>
<p><span class="Bold">What are the possible side effects of lamotrigine tablets, USP? </span></p>
<ul><li> See “What is the most important information I should know about lamotrigine tablets??  </li></ul>
<p>Common side effects of lamotrigine tablets include: </p>
<a name="id_4e82fa62-a664-4730-a58f-1dedd8809f18"></a><table width="444.000">
<col width="50.0%">
<col width="50.0%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li></ul></td>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></li></ul></td>
</tr>
<tr>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li></ul></td>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li></ul></td>
</tr>
<tr>
<td align="left" valign="top"><ul><li>blurred or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span></li></ul></td>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li></ul></td>
</tr>
<tr>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">lack of coordination</span></li></ul></td>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></li></ul></td>
</tr>
<tr>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></li></ul></td>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li></ul></td>
</tr>
<tr>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li></ul></td>
<td align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li></ul></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></li></ul></td>
<td class="Botrule" align="left" valign="top"><ul><li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li></ul></td>
</tr>
</tbody>
</table>
<p>Tell your healthcare provider about any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of lamotrigine tablets.  For more information, ask your healthcare provider or pharmacist.  </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1­800-FDA-1088.  </p>
<p><span class="Bold">How should I store lamotrigine tablets, USP?  </span></p>
<p>• Store lamotrigine tablets at room temperature between 68<span class="Sup">o</span>F to 77<span class="Sup">o</span>F (20<span class="Sup">o</span>C to 25<span class="Sup">o</span>C). <span class="Bold"> </span></p>
<p>• <span class="Bold">Keep lamotrigine tablets and all medicines out of the reach of children.  </span> </p>
<p><span class="Bold">General information about lamotrigine tablets, USP </span>  </p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lamotrigine tablets for a condition for which it was not prescribed. Do not give lamotrigine tablets to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>If you take a urine drug screening test, lamotrigine tablets may make the test result positive for another drug. If you require a urine drug screening test, tell the healthcare professional administering the test that you are taking lamotrigine tablets.  </p>
<p>This Medication Guide summarizes the most important information about lamotrigine tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about lamotrigine tablets that is written for healthcare professionals.  </p>
<p>For more information about Lamotrigine tablets, USP go to http://www.fda.gov. For medical inquiries or to report side effects regarding Lamotrigine tablets, USP please contact Apotex Corp., Drug Safety at 1-800-706-5575 or FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">What are the ingredients in lamotrigine tablets, USP? </span></p>
<p><span class="Bold">Lamotrigine Tablets, USP </span></p>
<p><span class="Bold">Active ingredient:</span> lamotrigine.  </p>
<p><span class="Bold">Inactive ingredients</span><span class="Bold">:</span> magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, sunset yellow aluminum lake (100-mg tablet only), ferric oxide, yellow (150-mg tablet only), and indigotine Al lake (200-mg tablet only).  </p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p><br>DEPAKENE<span class="Sup">®</span> and DEPAKOTE<span class="Sup">®</span> are registered trademarks of Abbott Laboratories.<span class="Bold"><br><br><span class="Bold">APOTEX INC.</span><br><span class="Bold">LAMOTRIGINE TABLETS, USP</span><br><span class="Bold">25 mg, 100 mg, 150 mg and 200 mg</span></span></p>
<table width="38%"><tbody class="Headless">
<tr class="First">
<td><span class="Bold">Manufactured by </span></td>
<td><span class="Bold">Manufactured for</span></td>
</tr>
<tr>
<td>Apotex Inc. </td>
<td>Apotex Corp.</td>
</tr>
<tr>
<td>Toronto, Ontario </td>
<td>Weston, Florida</td>
</tr>
<tr class="Last">
<td>Canada M9L 1T9 </td>
<td>33326, USA</td>
</tr>
</tbody></table>
<p><br>April 2015</p>
<p>Rev. 8</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_4361546d-a682-bf21-951b-a10303e8a1c6"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First">PRINCIPAL DISPLAY PANEL - 25 mg BOTTLE LABEL</p>
<p>Representative sample of labeling (see <span class="Bold"><a href="#HOW_SUPPLIED">HOW SUPPLIED</a></span> section of complete listing): </p>
<p><span class="Bold">APOTEX CORP. </span>NDC 60505-2663-1 </p>
<p><span class="Bold">Lamotrigine Tablets, USP</span></p>
<p><span class="Bold">25 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p><span class="Bold">100 bottle count</span></p>
<p><img alt="25mg-100btl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=25mg-100btl.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_28aa80f8-480a-2bad-52ba-d0de14a6147c"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First">PRINCIPAL DISPLAY PANEL - 100 mg BOTTLE LABEL</p>
<p><span class="Bold">APOTEX CORP.</span> NDC 60505-2664-1 </p>
<p><span class="Bold">Lamotrigine Tablets, USP</span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p><span class="Bold">100 bottle count</span></p>
<p><img alt="100mg-100btl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=100mg-100btl.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_9d419391-e9aa-26ff-ad99-57b198f88cb7"></a><a name="section-19"></a><p></p>
<h1></h1>
<p class="First">PRINCIPAL DISPLAY PANEL - 150 mg BOTTLE LABEL</p>
<p><span class="Bold">APOTEX CORP.</span> NDC 60505-2665-6 </p>
<p><span class="Bold">Lamotrigine Tablets, USP</span></p>
<p><span class="Bold">150 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p><span class="Bold">60 bottle count</span></p>
<p><img alt="150mg-60btl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=150mg-60btl.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_a4af73f6-fc7b-1122-80c7-2cdebb4d6486"></a><a name="section-20"></a><p></p>
<h1></h1>
<p class="First">PRINCIPAL DISPLAY PANEL - 200 mg BOTTLE LABEL</p>
<p><span class="Bold">APOTEX CORP.</span> NDC 60505-2680-6 </p>
<p><span class="Bold">Lamotrigine Tablets, USP</span></p>
<p><span class="Bold">200 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p><span class="Bold">60 bottle count</span></p>
<p><img alt="200mg-60btl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b057910-de40-3a17-2d52-8b520d5e0cbc&amp;name=200mg-60btl.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LAMOTRIGINE 		
					</strong><br><span class="contentTableReg">lamotrigine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-2663</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMOTRIGINE</strong> (LAMOTRIGINE) </td>
<td class="formItem">LAMOTRIGINE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LAM;25;APO</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-2663-3</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-2663-1</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:60505-2663-5</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:60505-2663-8</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:60505-2663-7</td>
<td class="formItem">74000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:60505-2663-0</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078625</td>
<td class="formItem">01/27/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LAMOTRIGINE 		
					</strong><br><span class="contentTableReg">lamotrigine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-2664</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMOTRIGINE</strong> (LAMOTRIGINE) </td>
<td class="formItem">LAMOTRIGINE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LAM;100;APO</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-2664-3</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-2664-1</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:60505-2664-5</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:60505-2664-8</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:60505-2664-0</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078625</td>
<td class="formItem">01/27/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LAMOTRIGINE 		
					</strong><br><span class="contentTableReg">lamotrigine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-2665</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMOTRIGINE</strong> (LAMOTRIGINE) </td>
<td class="formItem">LAMOTRIGINE</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LAM;150;APO</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-2665-3</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-2665-6</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:60505-2665-1</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:60505-2665-5</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:60505-2665-8</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:60505-2665-0</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078625</td>
<td class="formItem">01/27/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LAMOTRIGINE 		
					</strong><br><span class="contentTableReg">lamotrigine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-2680</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMOTRIGINE</strong> (LAMOTRIGINE) </td>
<td class="formItem">LAMOTRIGINE</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LAM;200;APO</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-2680-3</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-2680-6</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:60505-2680-5</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:60505-2680-8</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:60505-2680-0</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078625</td>
<td class="formItem">01/27/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Apotex Corp
							(845263701)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Apotex Inc. (209429182)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2fe4125e-4f7c-8155-dadb-2c517e248320</div>
<div>Set id: 9b057910-de40-3a17-2d52-8b520d5e0cbc</div>
<div>Version: 6</div>
<div>Effective Time: 20150506</div>
</div>
</div> <div class="DistributorName">Apotex Corp</div></p>
</body></html>
